Ascletis 
Welcome,         Profile    Billing    Logout  
 17 Products   379 Diseases  17 Products   171 Trials   3771 News 
223 Trials

   

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Pegasys (pegylated interferon α -2a) / Pharma& Schweiz
ACTRN12608000400369: A single-arm, open-label, pilot study evaluating the efficacy and safety of directly observed peginterferon alfa-2a with ribavirin in conjunction with a peer counsellor in patients actively using injecting drugs who have chronic hepatitis C and attend a drug and alcohol centre.

Recruiting
4
50
 
Dr Joe Sasadeusz, Roche Products Pty Ltd
Impact of standard pharmacotherapy treatment of chronic Hepatitis C virus (HCV) infection on: (i) quality of life, (ii) mental health status, (iii) injecting drug behaviours, and (iv) opioid pharmacotherapy use in active injecting drug users (IDUs)., Side effects related to chronic Hepatitis C virus (HCV) infection and treatment in active injecting drug users (IDUs)., Factors affecting compliance of active injecting drug users (IDUs) for standard pharmacotherapy treatment of chronic Hepatitis C virus (HCV) infection., Chronic hepatitis C virus (HCV) infection.
 
 
ChiCTR-ONRC-05000623: Treatment with Peginterferon Alfa-2a (40 KD) (PEGASYS?) of Chronic Hepatitis B Patients, Who Have Failed Anti-Viral Treatment? A Pilot Study

Completed
4
98
 
Peginterferon Alfa-2a (40 KD) (PEGASYS?) 180 mcq per week for 48 weeks versus placebo ;Peginterferon Alfa-2a (40 KD) (PEGASYS?) 180 mcq per week for 48 weeks versus placebo
Roche Hong Kong Limited; Level of the institution:, Hepatitis Research Fund
Viral Diseases
 
 
ChiCTR2000030000: An open, controlled clinical trial for evaluation of ganovo combined with ritonavir and integrated traditional Chinese and Western medicine in the treatment of novel coronavirus infection (COVID-19)

Recruiting
4
50
 
Ganovo/ ritonavir oral ;Pegasys injection ;Novaferon intramuscular injection+Spray inhalation ;Coriolus oral ;TCM+Spray inhalation
Nanchang Ninth Hospital; Nanchang Ninth Hospital, Ascletis Pharmaceuticals CO., LTD.
Pneumonia caused by new coronavirus
 
 
ChiCTR-TRC-10000770: Research of Combination Therapy of Western and Traditional Chinese Medicine on Chronic Hepatitis C

Completed
4
740
 
Binggan Granule 1, 1# bid for 12 months ;Pegasys 180ug qw+Ribavirin 300mg tid+Binggan Granule 2, 1# bid for 12 months ;Binggan Granule 2, 1# bid for 12 months ;Pegasys 180ug qw+Ribavirin 300mg tid+Binggan Granule 1, 1# bid for 12 months
Shuguang Hospital Affiliated to Shanghai Univercity of Traditional Chinese Medicine; Level of the institution:, Ministry of Health, China
Chronic hepatitis C
 
 
2010-023245-30: Treatment with Peg-interferon alfa-2a and ribavirin in patients with hepatitis HCV-related, with or without HIV co-infection, and end stage renal disease on dialysis

Ongoing
4
20
Europe
Tablet, Solution for injection, COPEGUS*168CPR RIV 200MG, PEGASYS*SC SIR 0,5ML 180MCG+AG
ISTITUTO NAZIONALE DELLE MALATTIE INFETTIVE LAZZARO SPALLANZANI
Chonic hepatitis HCV-related
 
 
NCT01006512: Peginterferon Plus Ribavirin for Hepatitis C Patients Concomitant With Malignancy Other Than Hepatocellular Carcinoma

Recruiting
4
120
RoW
Peginterferon alfa-2a plus ribavirin, pegasys
Kaohsiung Medical University
Chronic Hepatitis C, Neoplasms
06/11
06/11
ChiCTR-TRC-10000926: A phase IV study on optimizing Pegasys plus Ribavirin treatment in difficult-to-treat Chronic Hepatitis C treatment naive patients.

Completed
4
440
 
The subjects who meet EVR will be treated as follows: Pegasys 180μg/wk plus Ribavirin 10.6-15mg/kg/day for totally 48 weeks. ;The rest patients who fail to reach EVR will be randomized (1:1) into 2 study arms as follows: Pegasys 180μg/wk plus Ribavirin 10.6-15mg/kg/day for totally 72 weeks. ;The rest patients who fail to reach EVR will be randomized (1:1) into 2 study arms as follows: Pegasys 180μg/wk plus Ribavirin 10.6-15mg/kg/day for totally 96 weeks
Peking University People's Hospital; Ministry of Health, National S&T Major Project for Infectious Diseases Control
chronic hepatitis C
 
 
ChiCTR-TRC-10000915: A phase IV study on optimizing Pegasys plus Ribavirin in the treatment of non-respond Chronic Hepatitis C patients

Completed
4
100
 
Pegasys 180ug/wk plus Ribavirin 10.6-15mg/kg/day for 72 weeks ;Pegasys 180ug/wk plus Ribavirin 10.6-15mg/kg/day for 96 weeks
Peking University People's Hospital; Ministry of Health, National S&T Major Project for Infectious Diseases Control
chronic hepatitis C
 
 
ChiCTR-TRC-10000916: A phase IV study on optimizing Pegasys plus Ribavirin for paitents with relapse chronic Hepatitis C

Completed
4
132
 
Pegasys 180μg/wk plus Ribavirin 10.6-15mg/kg/day for 48 weeks ;Pegasys 180μg/wk plus Ribavirin 10.6-15mg/kg/day for 72 weeks
Peking University People's Hospital; Ministry of Health, National S&T Key Project for Infectious Diseases Control
Chronic hepatitis C
 
 
ChiCTR-RNRC-10001089: A study on optimizing Pegasys or Peg IFN alpha-2b plus Ribavirin in the treatment of non-responsive Chronic Hepatitis C patients

Completed
4
100
 
Peg IFN alpha-2a is replaced by Peg IFNalpha-2b, Peg IFN alpha-2b 1.0-1.5ug/kg/wk plus Ribavirin 10.6-15mg/kg/day for 44 weeks after serum HCV RNA negative during 72-96 weeks ;PegIFN alpha-2a is replaced by PegIFNalpha-2b: PegIFNalpha-2b 1.0-1.5ug/kg/wk plus Ribavirin 10.6-15mg/kg/day for 72-96 weeks. Stop the medication if serum HCV RNA does not turn negative
3rd Hospital of HeiBei Medical University; Level of the institution:, Hebei Science and Technology Bureau
chronic hepatitis C
 
 
ChiCTR-TRC-09000612: Efficacy and safety of Pegasys combined with adefovir in the treatment of chronic hepatitis B with HBeAg(+)

Completed
4
120
 
Pegasys ;Pegasys combined with adefovir
Third Hospital Affiliated to Zhongshan University; Level of the institution:, Self-financing
Chronic hepatitis B with HBeAg(+).
 
 
ChiCTR-TRC-10001107: A phase IV study on optimizing Pegasys or Recombinant Human Interferonα2a pius Ribavirin for patients with relapse chronic Hepatitis C

Completed
4
132
 
PegIFN alpha-2a changed with Peg IFN alpha-2b , PegIFN alpha-2b 1.0-1.5ug/kg/wk, plus Ribavirin 10.6-15mg/kg/day for 44 weeks after serum HCV RNA negative during 72-96 weeks ;PegIFN alpha-2a changed with PegIFN alpha-2b, PegIFN alpha-2b 1.0-1.5ug/kg/wk, plus Ribavirin 10.6-15mg/kg/day for 72-96 weeks without serum HCV RNA negative, then, PegIFN alpha-2b and Ribavirin were stopped
The Third Hospital of Hebei Medical University; Hebei Science and Technology Bureau, Hebei Science and Technology Bureau
chronic hepatitis C
 
 
ChiCTR-TRC-10001090: A study on optimizing Pegasys or Recombinant Human Interferon α-2b plus Ribavirin in treatment of na?ve patients with chronic hepatitis C.

Completed
4
260
 
The subjects will be treated as follows: Pegasys 180ug/wk plus Ribavirin 10.6-15mg/kg/day for 44 weeks after HCV RNA undetectable/clearance ;The rest patients will be treated as follows: IFNα-2b 500MU/2 days plus Ribavirin 10.6-15mg/kg/day for 44 weeks after HCV RNA undetectable /clearance
Third Hospital of HeiBei Medical University; Hebei Science and Technology Bureau, Hebei Science and Technology Bureau
chronic hepatitis C
 
 
2014-005388-34: Single arm prospective clinical study to evaluate the efficacy of combination therapy sofosbuvir+ribavirin+peg-interferon in experienced patients with HCV-GT1 Studio clinico prospettico a braccio singolo di fase IV per la valutazione dell’efficacia e della sicurezza della terapia combinata Sofosbuvir + Ribavirina + Interferone Peghilato in pazienti con epatite cronica da HCV GT1 che hanno già fallito un precedente ciclo di duplice terapia con Ribavirina + Interferone Peghilato

Ongoing
4
120
Europe
SOVALDI, PEGASYS, RIBAVIRINA, 34459014, Film-coated tablet, Solution for injection, Capsule, hard, SOVALDI - 400 MG - COMPRESSA RIVESTITA CON FILM - FLACONE (HDPE) - 28 COMPRESSE, PEGASYS - 180MCG-SOLUZ. INIETTABILE-USO SOTTOCUT.-PENNA PRERIEMPITA-0.5 ML (360MCG/ML) 12 PENNE PRERIEMPITE, REBETOL - 200 MG 84 CAPSULE RIGIDE IN BLISTER
AZIENDA OSPEDALIERA DI PADOVA, GILEAD SCIENCE S.R.L. - Italia
chronic hepatitis HCV GT1 who have already failed a prior course of dual therapy with pegylated interferon + ribavirin epatite cronica da HCV GT1 che hanno già fallito un precedente ciclo di duplice terapia con Ribavirina + Interferone Peghilato, chronic hepatitis HCV GT1 already treated epatite cronica da HCV GT1 già trattati, Diseases [C] - Virus Diseases [C02]
 
 
2015-003024-31: Protecting immune responses in patients treated with the new DAA anti hepatitis C alone or in combination with previously used medications (interferon and ribavirin) Risposte immunitarie proteggenti in pazienti trattati con i nuovi farmaci anti epatite C (nuovi DAA) da soli o in associazione con i farmaci precedentemente utilizzati (interferone e ribavirina)

Not yet recruiting
4
30
Europe
PEGINTERFERONE ALFA-2A, RIBAVIRINA, SOFOSBUVIR, LEDIPASVIR+SOFOSBUVIR, N.A., Solution for injection, Capsule, hard, Film-coated tablet, PEGASYS - 180MCG-SOLUZ. INIETTABILE-USO SOTTOCUT.-PENNA PRERIEMPITA-0.5 ML (360MCG/ML) 1 PENNA PRERIEMPITA, REBETOL - 200 MG 84 CAPSULE RIGIDE IN BLISTER, SOVALDI - 400 MG - COMPRESSA RIVESTITA CON FILM - FLACONE (HDPE) - 28 COMPRESSE, HARVONI - 90 MG/400 MG - COMPRESSE RIVESTITE CON FILM - USO ORALE - FLACONE (HDPE) - 28 COMPRESSE RIVESTITE CON FILM
AZIENDA OSPEDALIERO-UNIVERSITARIA DI PARMA, GILEAD SCIENCES SRL
CHRONIC HEPATITIS C EPATITE C CRONICA, CHRONIC HEPATITIS C EPATITE C CRONICA, Diseases [C] - Virus Diseases [C02]
 
 
2004-005112-83: RANDOMISED CONTROLLED STUDY ON EARLY RESPONSE TO COMBINED ANTIVIRAL THERAPY IN CHRONIC EPATITES C PATIENT GENOTIPE 1 AND 4 WITH HCV RNA NEGATIVE WEEK 6

Ongoing
4
100
Europe
PEGASYS, COPEGUS*168CPR RIV 200MG, PEGASYS, COPEGUS*168CPR RIV 200MG
AZIENDA SANITARIA OSPEDALIERA S. GIOVANNI BATTISTA DI TORINO
SOSTAINED BIOCHEMICAL AND VIROLOGICAL RESPONSE TO COMBINATED THERAPY PEGILATED RIBAVIRIN IN CHRONIC EPATITIES PATIENTS G 1 AND 4
 
 
2005-002452-17: Pilot, open, multicenter, phase IV Clinical Trial to evaluate safety and efficacy in treatment with peginterferon alfa-2a plus ribavirin in VIH patients with advanced immunosupression and chronic hepatopathy secondary to hepatitis C virus.

Ongoing
4
30
Europe
peginterferon alfa 2a, ribavirin, peginterferon alfa 2a, ribavirin, Pegasys 180 microgrames, Pegasys 135 microgrames, Copegus 200 mg, Pegasys 180 microgrames, Pegasys 135 microgrames, Copegus 200 mg
Hospital Universitario de Valme
¨Hepatitis C Crónica
 
 
2005-005650-41: A Comparative, Randomized, Open-label, Multicenter Study, of Directly Observed Treatment of Chronic Hepatitis C (DOT) and auto administrated treatment with Copegus® (Ro 20-9963) and Pegasys® (Ro 25-8310).

Ongoing
4
156
Europe
Pegasys, Copegus, Ro 25-8310, Ro 20-9963, Pegasys, Copegus, Pegasys, Copegus
SESP
Chronic Hepatitis C
 
 
2006-001243-55: Open, multicenter, phase IV study to evaluate the safety and effectiveness of peginterferon alfa-2a (40 KD) associated with ribavirin for the treatment chronic hepatitis C with persistent normal ALT in HIV coinfected patients

Ongoing
4
230
Europe
Pegasys, Copegus, Pegasys, Copegus, Pegasys, Copegus
Miguel Santin Cerezales
Comparate the safety and effectivenes of the treatment with peginterferon alfa-2a in combination with ribavirin between HIV/HCV coinfected patients with persistent normal ALT levels versus HIV/HCV coinfected patients with high ALT levels
 
 
2007-002743-24: Study to evaluate different duration of treatment regimes of 40kD pegylated interferon alfa 2a (Pegasys) plus ribavirin on sustained virological responses (SVR) in Genotype 3 HCV infected cirrhotic patients

Ongoing
4
140
Europe
Pegasys, Copegus, Pegasys, Copegus, Pegasys, Copegus
Queen Mary University of London
Chronic hepatitis C infection with genotype 3 and advanced fibrosis
 
 
2007-001122-27: Tailored treatment of hepatitis C genotype 1

Ongoing
4
100
Europe
Pegasys, Copegus, Ro25-8310/V01, R20-9963/J10, Pegasys, Copegus, Pegasys, Copegus
Västra Götalandsregionen
Chronic infection with hepatitis C virus, genotype 1, with signs of liver inflammation.
 
 
2007-007075-16: The effect of peroxisome proliferator activator receptor γ agonist pre-treatment on pegylated interferon-α2a and ribavirin efficacy in hepatitis C patients, previously resistant to treatment with pegylated interferon and ribavirin - a randomized-controlled trial -

Ongoing
4
50
Europe
Copegus, Actos, Pegasys, Actos, Pegasys
VU university medical center
Chronic hepatitis C infection
 
 
2009-012459-96: VALORACIÓN INTENSIVA DE LA CINÉTICA DEL RNA DEL VIRUS DE LA HEPATITIS C COMO PREDICTOR PRECOZ DE AUSENCIA DE RESPUESTA VIROLÓGICA SOSTENIDA EN PACIENTES CON HEPATITIS CRÓNICA POR VHC TRATADOS CON INTERFERON PEGILADO Y RIBAVIRINA

Ongoing
4
100
Europe
pegintron, ribavirina, PEGASYS, 180 microgramos, solución inyectable en jeringa precargada, PEGINTRON 150 microgramos polvo y disolvente para solución inyectable en pluma precargada, REBETOL 200 mg cápsulas duras, PEGASYS, 180 microgramos, solución inyectable en jeringa precargada, PEGINTRON 150 microgramos polvo y disolvente para solución inyectable en pluma precargada, REBETOL 200 mg cápsulas duras
Dr Calleja Panero
HEPATITIS C
 
 
ChiCTR-PPC-15006199: A Multi-center, Randomized, Controlled Clinical Trial of Pegylated interferon alpha-2a (40KD) Plus Ribavirin With or Without Vitamin D in Chronic Hepatitis C

Not yet recruiting
4
224
 
vitamin D supplementation with pegylated interferon + ribavirin (PegIFN/RBV) ;pegylated interferon + ribavirin (PegIFN/RBV)
The First Affiliated Hospital of Xinjiang Medical University; The First Affiliated Hospital of Xinjiang Medical University, Switzerland's Roche
Chronic hepatitis C
 
 
NCT03013556: Study on an Optimal Antiviral Treatment in HBeAg Positive Chronic Hepatitis B Patients

Recruiting
4
180
RoW
Group A, TDF, tenofovir, Group B:TDF then TDF and Peginterferon alfa-2a, tenofovir,pegasys, Group C:TDF and Peginterferon alfa-2a then TDF
Ruijin Hospital
Chronic Hepatitis
12/21
12/21
NCT03084250: The Investigation of Peginterferon Alfa-2a on Optimal in Chronic Hepatitis B Patients Who Have a High Risk of HCC

Active, not recruiting
4
150
RoW
Peginterferon Alfa-2A, Pegasys, Adefovir, entecavir,tenofovir, either of them
Shanghai Nanhui Nanhua Hospital
Hepatitis B
04/23
12/23
2011-001919-31: DALIAH A Danish Study of Low-dose Interferon Alpha Versus Hydroxyurea in the Treatment of Ph-negative Chronic Myeloid Neoplasias - A National Randomized Prospective Study With Focus on Efficacy, Toxicity and Quality of Life DALIAH Dansk Studie af Lav-dosis Interferon Alpha vs Hydroxyurea i Behandlingen af Ph-Negative kroniske myeloproliferative neoplasier “Et Nationalt Randomiseret Prospektivt Kvalitetssikringsstudie med Særlig Fokus på Effekt, Toxicitet og Livskvalitet”

Ongoing
3
200
Europe
Suspension for injection in pre-filled pen, Capsule, hard, Pegasys, PegIntron, Hydrea
Roskilde sygehus, Swedish Orphan, Ellen og Aage Fausbølls Helsefond af 1975, Fonden til lægevidenskabens Fremme, Odense Universitetshospitals forskningspulje, Region Sjællands og Region Syddanmarks fælles forskningspulje
Chronic myeloid neoplasms Essential thrombocythemia Polycythemia vera primary myelofibrosis Kroniske myeloide neoplasier Essential thrombocythemia Polycythemia vera primary myelofibrosis, Chronic myeloid neoplasms Essential thrombocythemia Polycythemia vera primary myelofibrosis Kroniske myeloide neoplasier Essential thrombocythemia Polycythemia vera primary myelofibrosis, Diseases [C] - Blood and lymphatic diseases [C15]
 
 
NCT01727323 / 2010-021337-31: A Study to Assess the Safety, Tolerability and Efficacy of TMC435 Along With Pegylated Interferon Alpha-2a (Pegasys) and Ribavirin (Copegus) Triple Therapy in Chronic Hepatitis C Genotype-1 Infected Patients Co-infected With Human Immunodeficiency Virus-Type 1

Active, not recruiting
3
109
US, Canada, Europe
TMC435, Pegylated interferon alpha-2a, Ribavirin
Janssen Research & Development, LLC, Janssen R&D Ireland, Tibotec Pharmaceuticals
Hepatitis C Virus Genotype-1
08/13
08/13
2014-000453-37: Treatment with association of two drugs (Viread and Pegasys) in patients with hepatitis B. TRATTAMENTO CON ASSOCIAZIONE DI DUE FARMACI (VIREAD E PEGASYS) NEI PAZIENTI AFFETTI DA EPATITE B

Ongoing
3
80
Europe
Viread, Pegasys, Tablet, Solution for injection, Viread, Pegasys
Azienda Ospedaliera di Padova, Azienda Ospedaliera di Padova
Hepatitis B virus (HBV) EPATITE CRONICA HBV-CORRELATA, Chronic liver disease caused by hepatitis B MALATTIA EPATICA CRONICA CAUSATA DAL VIRUS DELL’EPATITE B, Diseases [C] - Virus Diseases [C02]
 
 
2004-001622-24: Phase III,multicentre,open-label,prospective randomised trial comparing Imatinib alone at 400mg versus 800mg daily versus Imatinib 400mg daily plus PEG Interferon-alpha with newly diagnosed chronic myeloid leukaemia

Ongoing
3
50
Europe
Glivec, Pegasys, Glivec (400mg), Glivec (800mg), Pegasys, Glivec (400mg), Glivec (800mg), Pegasys
Newcastle Hospital Trust
Chronic Myeloid Leukaemia (Chronic Phase)
 
 
2006-000853-23: Prospektivní, otevřená, randomizovaná multicentrická studie hodnotící účinnost a bezpečnost pegylovaného interferonu alfa 2a (Pegasys) v adjuvantní léčbě rizikového primárního kožního melanomu

Ongoing
3
252
Europe
Pegasys 180 mikrogramů, Roferon®-A, EU/1/02/221/008, 44/396/96-C, 44/160/99-C, 44/161/99-C, 44/086/02-C,
Kožní ordinace
Chirurgicky adekvátně odstraněný a histologicky verifikovaný primární kožní melanom ve stadiu IIB až IIIB podle nové AJCC 2003 klasifikace.
 
 
2006-006042-33: A pilot, open label, multicenter, randomized clinical trial on Lopinavir/Ritonavir-monotherapy vs Lopinavir/Ritonavir plus selected Nucs, in HIV/HCV coinfected patients with chronic hepatitis C or compensated cirrhosis, starting treatment with Ribavirin and Pegylated Interferon

Ongoing
3
50
Europe
KALETRA, COPEGUS, PEGASYS, KALETRA, COPEGUS, PEGASYS
OSPEDALE S. RAFFAELE
patients affected by HIV and chronic HCV or compensated cirrhosis
 
 
2006-005996-17: A pilot, open label, multicenter, randomized clinical trial on Lopinavir/ritonavir-monotherapy vs Lopinavir/ritonavir plus selected Nucs, in HIV/HCV ARV-naive coinfected patients with chronic hepatitis C or compensated cirrhosis, starting treatment with Ribavirin and Pegylated Interferonヤ

Ongoing
3
60
Europe
KALETRA, PEGASYS, COPEGUS, KALETRA, PEGASYS, COPEGUS
OSPEDALE S. RAFFAELE
PATIENTS AFFECTED BY HIV/HCV NAIVES FROM THERAPIES
 
 
2005-003648-70: Randomised, double-blinded phase IIIb study to optimise antiviral therapy response of a standard therapy consisting of peginterferon-alfa-2a and ribavirin plus the additional use of bezafibrat 400 mg/d in untreated patients with chronic hepatits C typ 1.

Ongoing
3
414
Europe
Cedur retard, Pegasys, Copegus, Cedur retard, Pegasys, Copegus
Charité Universitätsmedizin Berlin
First time treatment in chronic hepatitis C-infection patients with elevated GGT-level without coinfections as HBV, HDV and HIV
 
 
2006-006985-41: Estudio piloto en fase III, mutlicéntrico, aleatorizado, controlado y abierto, sobre la eficacia de Interferón Pegilado alfa-2a a dosis de 90 mcg semanal en retrasar la aparición del primer evento de descompensación hepática en pacientes con cirrosis hepática por virus C nunca descompensada y con coinfección por VIH, en los que el tratamiento estándar con Interferón Pegilado ha fracasado. Estudio IRISH.

Ongoing
3
220
Europe
PEGASYS (PEGINTERFERON ALFA-2A), PEGASYS (PEGINTERFERON ALFA-2A)
JOAQUIN PORTILLA
PACIENTES CON CIRROSIS HEPATICA (CH) POR VIRUS C NUNCA DESCOMPENSADA Y COINFECTADOS POR EL VIH QUE NO HAN RESPONDIDO AL TRATAMIENTO ESTANDAR CON INTERFERON PEGILADO Y RIBAVIRINA
 
 
2008-006453-40: Peg-INF alfa-2a plus ribavirin treatment of liver transplant patients with hepatitis C relaps on protocol liver biopsies - a Nordic study on rapid viral response, early viral response, end of treatment response and sustained viral response rates

Ongoing
3
100
Europe
Pegasys, Copegus, Pegasys 180 mcg / 135 mcg, Copegus 200 mg / 400 mg, Pegasys 180 mcg / 135 mcg, Copegus 200 mg / 400 mg
Karolinska University hospital Huddinge
Chronic hepatitis C infection
 
 
2009-018146-38: Multicenter randomized controlled study comparing the efficacy and safety of natural Multi-subtype interferon alpha (Multiferon) in association with ribavirin versus retreatment with pegylated interferon-alpha 2a and ribavirin in non-responding genotype 1 hepatitis C patients.

Ongoing
3
110
Europe
Multiferon, Pegasys, Copegus, Multiferon, Pegasys, Copegus
Swedish Orphan International AB
Hepatitis C
 
 
2010-019501-41: A randomized study comparing two drugs: hydroxyurea and Pegylated Interferon Alfa-2a, in an open label clinical trial in two independent diseases: (1) high risk polycythaemia vera and (2) high risk essential thrombocythaemia.

Ongoing
3
95
Europe
peginterferon alfa-2a, Hydroxyurea, Pegasys, Pegasys, Hydroxyurea, Pegasys, Hydroxyurea
CONSORZIO MARIO NEGRI SUD, Consorzio Mario Negri Sud, Myeloproliferative Disease Research Consortium (MPD-RC), Myeloproliferative Disorders Research Consortium, National Cancer Institute, F.Hoffmann-La Roche, Cancer Research UK, MPD-RC
The myeloproliferative disorders essential thrombocythaemia (ET) and polycythaemia vera (PV).
 
 
NCT01369212: Combination Therapy of Pegylated Interferon Alfa-2a and Tenofovir Versus Tenofovir Monotherapy in Chronic Hepatitis B

Completed
3
201
Canada, US
Tenofovir, Hepatitis B, Viread, Peginterferon-alfa 2a and tenofovir, PEGASYS, tenofovir
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), University of Pittsburgh, National Center for Research Resources (NCRR)
Hepatitis B
03/21
03/21
D-LIVR, NCT03719313 / 2018-003167-54: Study of the Efficacy and Safety of Lonafarnib / Ritonavir With and Without Pegylated Interferon -Alfa-2a

Completed
3
407
Europe, Canada, US, RoW
Lonafarnib, EBP994, Sarasar, LNF, Ritonavir, Norvir, RTV, PEG IFN-alfa-2a, Pegasys, pegylated interferon-alfa, Placebo Lonafarnib, Placebo Ritonavir
Eiger BioPharmaceuticals
Hepatitis Delta Virus
10/22
03/23
ACTRN12605000041651: Phase II trial of Pegasys in Glivec responsive chronic phase chronic myeloid leukaemia

Completed
2
60
 
Australasian Leukaemia and Lymphoma Group, Novartis Australia, Roche Australi
Chronic myeloid leukaemia
 
 
2010-019500-23: Therapy with Pegylated Interferon Alfa-2a for Patients with Polycythemia Vera or Essential Thrombocythemia who are Either Hydroxyurea Resistant or Intolerant Or have had Abdominal Vein Thrombosis. Terapia con l'interferone Alfa-2a (PEGASYS) Peghilato per i pazienti con Policitemia Vera o Trombocitemia Essenziale che sono resistenti o intolleranti al trattamento con Hydroxyurea o che hanno avuto una trombosi della vena spalcnica.

Ongoing
2
188
Europe
Solution for injection, Peginterferon PFS
CONSORZIO MARIO NEGRI SUD, Myeloproliferative Disorders-Research Consortium
High risk polycythemia vera and high risk essential thrombocythemia Policitemia Vera (PV) ad alto rischio o Trombocitemia Essenziale (ET) ad alto rischio, polycythemia vera or essential thrombocythemia Policitemia Vera o Tromcitemia Essenziale, Diseases [C] - Blood and lymphatic diseases [C15]
 
 
2014-003894-41: Effect of Interferon on protecting immune response in chronic hepatitis B patients under treatment for the infection with standard antiviral therapy Effetto dell’Interferone sulla risposta immunitaria proteggente in pazienti con epatite B cronica già in trattamento per l’infezione con terapia antivirale standard

Ongoing
2
80
Europe
Peginterferone alfa-2a, Entecavir, Tenofovir Disoproxil, Solution for injection in pre-filled syringe, Tablet, Pegasys, Baraclude, Viread
Azienda Ospedaliero-Universitaria di Parma, F. Hoffmann - La Roche Ltd, Gilead Sciences srl, Regione Emilia-Romagna
Chronic hepatitis B infection Infezione da Epatite B cronica, Chronic hepatitis B infection Infezione da Epatite B cronica, Diseases [C] - Virus Diseases [C02]
 
 
2014-000815-15: add-on therapy of HBV chronic infection Terapia di associazione sequenziale della epatite B cronica

Ongoing
2
40
Europe
pegylated interferon alpha 2a, Suspension for injection in pre-filled pen, Pegasys
Azienda Ospedaliera, Polo Universitario Luigi Sacco, Milano, Università degli Studi di Milano
Chronic hepatitis B Epatite B cronica, Chronic Hepatitis B epatite B cronica, Diseases [C] - Virus Diseases [C02]
 
 
2013-003295-12: Kombinationsbehandling med Interferon og JAK1-2 Hæmmer i behandlingen af Ph-Negativ Myeloprolifertiv Cancer

Ongoing
2
50
Europe
Jakavi, Jakavi, Pegasys 135 microgram, PegIntron 50 microgram, Jakavi, Pegasys 135 microgram, PegIntron 50 microgram
Roskilde University Hospital, Novartis
Polycythemia vera Hyperproliferativ myelofibrosis, Diseases [C] - Blood and lymphatic diseases [C15]
 
 
2016-001010-17: Treatment withdrawal in patients with hepatitis B virus infection to promote clearance of the virus from the body

Ongoing
2
240
Europe
Peginterferon alfa-2a, Solution for injection in pre-filled syringe, Pegasys
Imperial College, London, NIHR EME
Hepatitis B viral infection, Hepatitis B viral infection, Diseases [C] - Virus Diseases [C02]
 
 
2017-001647-12: A study to determine how safe the treatment is for subjects diagnosed with hepatitis B virus infections when combined with other treatments for hepatitis B. Subjects must have no evidence of liver damage. Un estudio para determinar la seguridad del tratamiento para los sujetos diagnosticados con infecciones por el virus de la hepatitis B cuando se combinan con otros tratamientos para la hepatitis B. Los sujetos no deben tener evidencia de daño hepático.

Ongoing
2
20
Europe
ARB-001467, Viread, Pegasys, ARB-001467, Solution for infusion, Film-coated tablet, Solution for injection in pre-filled syringe, Viread, Pegasys
Arbutus Biopharma Corporation, Arbutus Bipoharma Corporation
Hepatitis B virus e-antigen (HBeAg)-negative subjects with chronic hepatitis B virus infection (CHB) Pacientes con infección crónica por el virus de la hepatitis B (HBC) HBeAg-negativo sin cirrosis, Subjects infected with hepatitis B virus Los sujetos infectados con el virus de la hepatitis B, Diseases [C] - Virus Diseases [C02]
 
 
2018-004150-13: Combination Therapy with Interferon-Alpha2a and Ruxolitinibin Newly Diagnosed Patients with Polycythemia Vera.A Danish Safety and Efficacy Study.

Not yet recruiting
2
25
Europe
Tablet, Injection, Jakavi, Pegasys
Zealand University hospital, Novartis
Polycythemia Vera, Polycythemia Vera, Diseases [C] - Blood and lymphatic diseases [C15]
 
 
2019-001485-15: This study will use an investigational product (bulevirtide) for the treatment of chronic hepatitis Delta to learn the therapeutic effect, and safety of the drug in humans.

Ongoing
2
175
Europe
Bulevirtide, Lyophilisate for solution for injection, Solution for injection, Pegasys
MYR GmbH, MYR GmbH
Chronic Hepatitis Delta, Chronic Hepatitis Delta, Diseases [C] - Virus Diseases [C02]
 
 
2019-004978-26: A clinical study to evaluate efficacy, pharmacokinetics, safety, and tolerability of response-guided treatment with JNJ-73763989 + JNJ-56136379 + nucleos(t)ide analog regimen with or without pegylated interferon alpha-2a in treatment-naïve patients with HBeAg positive chronic hepatitis B virus infection.

Not yet recruiting
2
80
Europe
JNJ-73763989, JNJ-56136379, Solution for injection, Tablet, Film-coated tablet, Solution for injection in pre-filled syringe, Tenofovir disoproxil Mylan 245 mg film-coated tablets, Vemlidy 25 mg film-coated tablets, Pegasys 180 micrograms solution for injection in pre-filled syringe
Janssen-Cilag International NV, Janssen Sciences Ireland Unlimited Company
Chronic Hepatitis B Virus Infection, Chronic Hepatitis B Virus Infection, Diseases [C] - Virus Diseases [C02]
 
 
2021-002450-81: A Clinical Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of Treatment With JNJ-73763989, Nucleos(t)ide Analogs, and Pegylated Interferon Alpha-2a in Patients With Chronic Hepatitis B Virus Infection. Estudio clínico para evaluar la eficacia, seguridad, tolerabilidad y farmacocinética del tratamiento con JNJ-73763989, análogos de nucleos(t)ido e interferón pegilado alfa-2a en pacientes con infección crónica por el virus de la hepatitis B.

Ongoing
2
102
Europe
JNJ-73763989, Solution for injection, Film-coated tablet, Solution for injection in pre-filled syringe, Entecavir Mylan 0.5 mg film-coated tablets, Viread 245 mg film-coated tablets, Vemlidy 25 mg film-coated tablets, Pegasys 180 micrograms solution for injection in pre-filled syringe
Janssen-Cilag International NV, Janssen Research and Development LLC
Chronic Hepatitis B Virus Infection Infección crónica por el virus de la hepatitis B, Chronic Hepatitis B Virus Infection Infección crónica por el virus de la hepatitis B, Diseases [C] - Virus Diseases [C02]
 
 
2021-001033-39: A Phase 2 Study to Evaluate the Safety, Tolerability, and Efficacy of Regimens Containing VIR -2218, VIR-3434, and/or PEG-IFNα in Subjects with Chronic Hepatitis B Virus Infection

Not yet recruiting
2
260
Europe
Pegasys, VIR-2218, VIR-3434, NA, Solution for injection, Lyophilisate for solution for injection, Pegasys
Vir Biotechnology, Inc., Vir Biotechnology, Inc.
Chronic HBV infection., Chronic infection of Hepatitis B Virus., Diseases [C] - Immune System Diseases [C20]
 
 
SWITCH-1, NCT02583685: Switching Regimen in Treating Cirrhotic HCV GT1b Subjects

Completed
2
138
RoW
PR4 + LDV/SOF + ASV 4 wk, Pegasys®, Copegus®, Harvoni®, Sunvepra®, PR4 + LDV/SOF + SMV 4 wk, OLYSIO®, PR4 + LDV/SOF + ASV 6 wk, PR4 + LDV/SOF + SMV 6 wk, PR4 + LDV/SOF + ASV 8 wk, PR4 + LDV/SOF + SMV 8 wk, PR4 + LDV/SOF + ASV 12 wk, PR4 + LDV/SOF + SMV 12 wk
Humanity and Health Research Centre, Beijing 302 Hospital, Nanfang Hospital, Southern Medical University
Chronic Hepatitis C Infection
10/24
10/24
2020-003956-34: A Clinical Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of Treatment With JNJ-73763989, JNJ-56136379, Nucleos(t)ide Analogs, and Pegylated Interferon Alpha-2a in Virologically Suppressed Patients With Chronic Hepatitis B Virus Infection.

Not yet recruiting
2
50
Europe
JNJ-73763989, Solution for injection, Film-coated tablet, Solution for injection in pre-filled syringe, Viread 245 mg film-coated tablets, Vemlidy 25 mg film-coated tablets, Entecavir Mylan 0.5 mg film-coated tablets, Pegasys 180 micrograms solution for injection in pre-filled syringe
Janssen-Cilag International NV, Janssen Research and Development LLC
Chronic Hepatitis B Virus Infection, Chronic Hepatitis B Virus Infection, Diseases [C] - Virus Diseases [C02]
 
 
NCT04426968: A Phase II Study of Hepalatide in Subjects With Chronic Hepatitis B

Completed
2
96
RoW
Hepalatide 2.1mg, L47, Hepalatide 4.2mg, Hepalatide 6.3mg, placebo 2.1mg, placebo 4.2mg, placebo 6.3mg, Pegylated Interferon, Pegasys
Shanghai HEP Pharmaceutical Co., Ltd.
Hepatitis B, Chronic
11/23
11/23
NCT00452023: Pegasys® in Patients With Myeloproliferative Diseases

Completed
2
83
US
IFN-alpha2a, Pegylated-Interferon Alpha-2A, PEG-IFNa-2a, Pegasys
M.D. Anderson Cancer Center
Myeloproliferative Disorders
05/23
05/23
NCT05244057: A Study of Hepalatide Combined With TAF and PEG-IFN as Finite Treatment of Chronic Hepatitis B Patients

Completed
2
8
RoW
Hepalatide, L47, Placebo of Hepalatide, Placebo, Tenofovir Alafenamide Tablets, Vemlidy, Pegylated Interferon alfa 2a, Pegasys
Shanghai HEP Pharmaceutical Co., Ltd., Shanghai Tong Ren Hospital, Shanghai East Hospital
Chronic Hepatitis B
06/24
06/24
Piranga, NCT04225715 / 2019-002086-35: A Trial To Evaluate The Efficacy And Safety Of Multiple Combination Therapies In Participants With Chronic Hepatitis B

Completed
2
281
Europe, Canada, US, RoW
Nucleos(t)ide (NUC), CpAM (RO7049389), TLR7 (RO7020531), siRNA (RO7445482), PEG-IFN, Pegasys®, PD-L1 LNA (RO7191863)
Hoffmann-La Roche
Hepatitis B, Chronic
07/24
07/24
ALPHAGEM, NCT05941845: Interferon Alfa Therapy Based on Th17 Profile in Membranous Nephropathy

Not yet recruiting
2
5
Europe
Peginterferon Alfa-2A 180 MCG/ML Injectable Solution, Pegasys®, interferon alfa
Centre Hospitalier Universitaire de Nice
Membranous Nephropathy
01/25
07/25
IPOS, NCT04798612: Effect of Low-dose Interferon-alfa2a on Peri-operative Immune Suppression

Recruiting
2
68
Europe
Pegasys, Saline
Zealand University Hospital, University of Copenhagen
Colon Cancer
08/25
12/25
MoST-TAP, NCT06003621: Tiragolumab and Atezolizumab in Advanced Pan-cancer Patients

Recruiting
2
96
RoW
Tiragolumab, RO7092284, MTIG7192A, RG-6058, Anti-TIGIT, Atezolizumab, Tecentriq, MPDL3280A, RG7446, RO5541267
Omico, Hoffmann-La Roche, The George Institute for Global Health, Australia
Solid Tumor, Adult
05/26
11/28
FAIM, NCT04920708: Fulvestrant, Ipatasertib and CDK4/6 Inhibition in Metastatic ER+/HER2- Breast Cancer Patients Without ctDNA Suppression

Recruiting
2
324
Europe
Ipatasertib 300mg, RG7440, Fulvestrant 500g, Faslodex, Palbociclib 75mg-125mg, Ibrance, CDK4/6 Inhibitor, Abemaciclib / Ribociclib / Palbociclib
Royal Marsden NHS Foundation Trust, Pfizer, Hoffmann-La Roche
Metastatic Breast Cancer, ER+ Breast Cancer, Advanced Breast Cancer
09/26
09/26
ACTIVATE, NCT02471430: Reducing the Residual Reservoir of HIV-1 Infected Cells in Patients Receiving Antiretroviral Therapy

Completed
1/2
17
US
Panobinostat, Farydak, LBH589, Pegylated Interferon-alpha2a, Pegasys
Massachusetts General Hospital, Novartis, Genentech, Inc.
HIV Infection
08/22
12/23
NCT04943679: Anti-PD-1/PD-L1 Antibodies Plus Pegylated Interferon Alfa-2b Treatment in Patients With Advanced-Stage HCC

Recruiting
1/2
15
RoW
Anti-PD-1/PD-L1, PEG-Interferon Alfa, Pegasys
Shanghai Zhongshan Hospital
Hepatocellular Carcinoma
12/24
12/24
MORPHEUS BC, NCT04802759: A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer

Recruiting
1/2
316
Europe, US, RoW
Giredestrant, GDC-9545, RO7197597, RG6171, Abemaciclib, Verzenio™, Ipatasertib, GDC-0068, RO5532961, RG7440, Inavolisib, GDC-0077, RO7113755, RG6114, Ribociclib, Kisqali®, Everolimus, Afinitor®, Samuraciclib, ICEC0942, CT7001, PH FDC SC, Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf, PHESGO™, RO7198574, RG6264, Palbociclib, Ibrance®, Atezolizumab, Tecentriq®, RO5541267, RG7446
Hoffmann-La Roche
Inoperable, Locally Advanced or Metastatic, ER-positive Breast Cancer
11/27
11/27
ChiCTR-OPQ-14005299: Tolerance, pharmacokinetics and pharmacodynamics of PEG-INF-alpha 2b in healthly volunteers: A Randomized, Single center, drug control, Open-Label study

Recruiting
1
58
 
PegIntron subcutaneously ;PEGASYS subcutaneously ;hypodermic
West China Hospital, Sichuan University; West China Hospital, Sichuan University, ANHUI ANKE BIO TECNOLOGY(GROUP) CO.,LTD
Chronic hepatitis B and C
 
 
NCT06144697: A Study to Evaluate the Safety, Tolerability, Drug Levels, Food, Formulation, and pH Effects on Relative Absorption of BMS-986465 and Its Active Derivative BMS-986464 in Healthy Participants

Terminated
1
267
US
BMS-986465, Placebo, Pegasys, Famotidine
Bristol-Myers Squibb
Healthy Participants
10/24
10/24
NCT05729139: Cemiplimab/Peg-Interferon-α in Advanced CSCC

Withdrawn
1
21
US
Cemiplimab-Rwlc, Libtayo, PEG-IFN alfa-2a, PEGASYS
Baptist Health South Florida, Regeneron Pharmaceuticals
Cutaneous Squamous Cell Carcinoma, Squamous Cell Carcinoma, Advanced Squamous Cell Carcinoma
07/26
07/28
ChiCTR-TRC-12002116: A multi-center randomized controlled clinical trial on treatment of chronic hepatitis C using Vitamin D combine pegylated interferon + ribavirin

Completed
N/A
200
 
vitamin D + peg-INF-alpha-2a ;peg-INF-alpha-2a
Department of Infectious Deases of First Teaching Hospital of Xinjiang Medical University; Department of Infectious Deases of First Teaching Hospital of Xinjiang Medical University, Roche China (Shanghai)
Hepatitis C
 
 
AV-FLCHB, NCT06535048: Impact of Fatty Liver on Hepatitis B Therapy

Active, not recruiting
N/A
500
NA
Entecavir;Tenofovir Disoproxil Fumarate (TDF); Tenofovir alafenamide fumarate (TAF);Interferons, Entecavir: Baraclude, Tenofovir Disoproxil Fumarate (TDF): Viread, Tenofovir Alafenamide Fumarate (TAF): Vemlidy, Pegylated Interferon Alpha (Peg-IFN-α): Pegasys
Tianjin Second People's Hospital
Fatty Liver Disease, Chronic Hepatitis B, Antiviral Treatment
06/19
08/24
NCT03957629: Optimized Treatment of Peginterferon Alfa 2a in Treatment Experienced Patients With HBV Related Liver Fibrosis

Recruiting
N/A
186
RoW
Tenofovir Disoproxil Fumarate, Viread, Beixin, PEG-Interferon alfa 2a, Pegasys
Third Affiliated Hospital, Sun Yat-Sen University
Hepatitis B, Liver Fibrosis
07/21
07/23
RCAP, NCT05683548: Replicor Compassionate Access Program

No Longer Available
N/A
Europe, RoW
REP 2139-Mg, Tenofovir Disoproxil Fumarate, Viread, Pegylated interferon alpha2a, Pegasys
Replicor Inc.
Viral Hepatitis B, Viral Hepatitis D, Cirrhosis, Liver, Decompensated Cirrhosis, Ascites Hepatic, Varices, Esophageal, Hepatocellular Carcinoma
 
 
HERACLIS-BLV, NCT05928000: HEllenic Multicenter ReAl-life CLInical Study for Bulevirtide Therapy in Chronic Hepatitis D:

Recruiting
N/A
80
Europe
Bulevirtide, Entecavir, Tenofovir, Pegasys
University of Athens
Hepatitis D
11/23
12/23
NCT03771677: To Optimize the Therapeutic Pathway of Peginterferon Treatment in Patients With CHB Based on IFNA2p.Ala120Thr /ISGs.

Recruiting
N/A
400
RoW
Nucleotide Analog, Nucleotide Analogs, Interferon Alfa-2A, Pegasys
Sun Yat-sen University, First People's Hospital of Foshan, Eighth Affiliated Hospital, Sun Yat-sen University
Hepatitis B
12/23
12/24
Ganovo (danoprevir) / Roche, Ascletis, Pfizer
ChiCTR1800019812: The efficacy and safety of 12-week ritonavir-boosted danoprevir plus pegylated interferon and ribavirin treatment of CHC genotype 1 patients experienced DAA failure: a multi-center, open labeled clinical trial

Not yet recruiting
4
30
 
12 weeks treatment, 12weeks follow-up
the 2nd affiliated hospital of Chongqing Medical School; Ascletis Pharmaceuticals Co., Ltd., Response by Ascletis Pharmaceuticals Co.,Ltd
HCV
 
 
ChiCTR2000040851: The pharmacokinetics of single and multiple doses of ASC16 quadruplex administration

Completed
1
64
 
ASC16 (200 mg, 1 tablet) ;ASC08 (100 mg, 1tablet) ;RTV (100 mg, 1tablet) ;RBV (500 mg, 5tablet) ;ASC16 (200 mg, 1 tablet) +ASC08/ R (100 mg/100 mg, 1 tablet /1 tablet) + RBV (500 mg, 5 tablets) ;Group F: ASC16 (200 mg, 1 tablet, QD) + ASC08/ R (100 mg/100 mg, 1 tablet /1 tablet, BID) + RBV (500 mg, 5 tablets, BID)
Nanning Second People's Hospital; Ascletis BioScience Co., Ltd., self-finance
Basic Science
 
 
ChiCTR2000030259: Evaluation Danoprevir sodium tablets combined with ritonavir in the treatment of novel coronavirus pneumonia (COVID-19): a randomized, open and controlled trial

Recruiting
N/A
60
 
Danoprevir sodium tablets,/ritonavir oral ;Symptomatic treatment
Shanghai Changzheng Hospital; Shanghai Changzheng Hospital, Ascletis Pharmaceuticals CO., LTD.
Novel Coronavirus Pneumonia (COVID-19)
 
 
ChiCTR2000031734: Evaluation Danoprevir sodium tablets combined with ritonavir in the treatment of novel Coronavirus Pneumonia (COVID-19): a randomized, open-label, controlled trial

Recruiting
N/A
40
 
Danoprevir sodium tablets,/ritonavir oral
Huoshenshan Hospital; Huoshenshan Hospital, Ascletis Pharmaceuticals CO., LTD.
Novel Coronavirus Pneumonia (COVID-19)
 
 
ChiCTR2000030472: An open and controlled clinical study to evaluate the efficacy and safety of Ganovo combined with ritonavir in the treatment of novel coronavirus pneumonia (COVID-19)

Recruiting
N/A
20
 
Ganovo/ ritonavir oral+conventional treatment ;Conventional treatment
Shenyang Sixth People's Hospita; Shenyang Sixth People's Hospital, Government
Novel Coronavirus Pneumonia (COVID-19)
 
 
C-DIAMOND, NCT04952207: Effectiveness and Safety of Direct-Acting Antiviral Agents for the Treatment of Chronic Hepatitis C

Recruiting
N/A
300
RoW
Direct-acting antiviral agents, daclatasvir, asunaprevir, ombitasvir, paritaprevir, dasabuvir, sofosbuvir, velpatasvir, ledipasvir, elbasvir, grazoprevir, danoprevir, glecaprevir, pibrentasvir, voxilaprevir
Qing XIe, Gilead Sciences, Tigermed Consulting Co., Ltd
Hepatitis C, Chronic
07/21
08/21
Asclevir (ravidasvir) / Presidio Pharma, Ascletis, Pharco Pharmaceuticals
STORM-C-1, NCT02961426: Strategic Transformation of the Market of HCV Treatments

Active, not recruiting
2/3
603
RoW
sofosbuvir + ravidasvir, ravisdasvir: PPI-668
Drugs for Neglected Diseases, Ministry of Health, Malaysia, Ministry of Health, Thailand, National Science and Technology Development Agency, Thailand
Hepatitis C
08/21
03/24
NCT04885855: 8- Versus 12-week of Sofosbuvir-ravidasvir Treatment of Chronic Hepatitis C

Completed
2/3
322
RoW
Sofosbuvir 400 MG, Grateziano, Ravidasvir 200mg, PPI-668
Muhammad Radzi Abu Hassan
Hepatitis C
12/23
03/24
ChiCTR2000041303: Study on the effect of food on ASC16 tablets pharmacokinetics

Completed
1
16
 
ASC16 tablet
Hu'nan Provincial Maternal and Child Health Care Hospital; Ascletis BioScience Co., Ltd., Self-finance
Basic Science
 
 
ASC-09 / J&J
ChiCTR2000029759: Retracted due to lack of patient A multicenter, randomized, open label, controlled trial for the efficacy and safety of ASC09/ Ritonavir compound tablets and Lopinavir/ Ritonavir (Kaletra) and Arbidol tablets in the treatm

Suspended
N/A
60
 
Lopinavir / Ritonavir (Kaletra) and IFN aerosol inhalation ;Abidol and IFN aerosol inhalation. ;ASC09/ Ritonavir (ASC09F) and IFN aerosol inhalation
The Second Affiliated Hospital of Chongqing Medical University; Chongqing Three Gorges Central Hospital, self-financing
Novel Coronavirus Pneumonia (COVID-19)
 
 
ChiCTR2000029603: A Randomized, Open-Label, Multi-Centre Clinical Trial Evaluating and Comparing the Safety and Efficiency of ASC09/Ritonavir and Lopinavir/Ritonavir for Confirmed Cases of Novel Coronavirus Pneumonia (COVID-19)

Recruiting
N/A
160
 
Conventional standardized treatment and ASC09/Ritonavir ;Conventional standardized treatment and Lopinavir/Ritonavir
The First Affiliated Hospital of Zhejiang University School of Medicine; The First Affiliated Hospital, Zhejiang University School of Medicine, Self-financing
novel coronavirus pneumonia (COVID-19)
 
 
denifanstat (TVB-2640) / Sagimet Biosci
NCT05118776: Study to Evaluate the Safety and Efficacy of ASC40 Tablets in Combination With Bevacizumab in Subjects With rGBM

Active, not recruiting
3
136
RoW
ASC40 tablets, TVB-2640, Placebo tablets, Bevacizumab
Ascletis Pharmaceuticals Co., Ltd.
Recurrent Glioblastoma
06/25
06/25
NCT06192264: A Study to Evaluate the Safety and Efficacy of ASC40 (Denifanstat) Tablets in the Treatment of Patients With Moderate to Severe Acne Vulgaris

Completed
3
480
RoW
ASC40
Ascletis Pharmaceuticals Co., Ltd.
Acne
05/25
05/25
NCT06248008: A Study to Evaluate Safety of ASC40 Tablets in Patients with Moderate to Severe Acne Vulgaris

Active, not recruiting
3
240
RoW
ASC40
Ascletis Pharmaceuticals Co., Ltd.
Acne
10/25
03/26
FASCINATE-3, NCT06594523: A Phase 3 Study Evaluating the Safety and Efficacy of Denifanstat in Patients With MASH and F2/F3 Fibrosis

Withdrawn
3
1260
NA
Denifanstat, TVB-2640, Placebo
Sagimet Biosciences Inc.
MASH, NASH, Metabolic Dysfunction-associated Steatohepatitis, Noncirrhotic Metabolic Dysfunction-associated Steatohepatitis, Nonalcoholic Steatohepatitis, Nonalcoholic Fatty Liver
12/30
12/30
FASCINIT, NCT06692283: A Phase 3 Study Evaluating the Safety and Efficacy of Denifanstat in Patients With MASLD and MASH

Withdrawn
3
2000
NA
denifanstat, TVB-2640, Placebo
Sagimet Biosciences Inc.
MASLD, MASH, NASH, Metabolic Dysfunction-Associated Steatotic Liver Disease, Metabolic Dysfunction-Associated Steatohepatitis, Nonalcoholic Steatohepatitis, Nonalcoholic Fatty Liver
06/26
06/27
NCT03032484: TVB- 2640 in Combination With Bevacizumab in Patients With First Relapse of High Grade Astrocytoma

Completed
2
25
US
Bevacizumab, Avastin, TVB-2640
The University of Texas Health Science Center at San Antonio
Astrocytoma
04/20
04/21
NCT05104125: Study to Evaluate the Safety and Efficacy of ASC40 in Subjects With Moderate to Severe Acne Vulgaris

Completed
2
180
RoW
ASC40 25mg, ASC40 50mg, ASC40 75mg, Placebo
Ascletis Pharmaceuticals Co., Ltd.
Acne Vulgaris
04/23
04/23
FASCINATE-2, NCT04906421: Study of TVB-2640 in Subjects With Nonalcoholic Steatohepatitis (NASH)

Hourglass May 2025 - May 2025 : Data for MASH
Completed
2
168
Europe, Canada, US
TVB-2640, Placebo
Sagimet Biosciences Inc.
Metabolic Dysfunction-assocated Steatohepatitis/ Nonalcoholic Fatty Liver Disease
10/23
10/23
NCT03808558: Phase 2 Study of TVB-2640 in KRAS Non-Small Cell Lung Carcinomas

Active, not recruiting
2
18
US
TVB-2640
David E Gerber, Sagimet Biosciences Inc., Cancer Prevention Research Institute of Texas, Gateway for Cancer Research
KRAS Gene Mutation
04/25
12/26
NCT03179904: TVB-2640 and Trastuzumab With Paclitaxel or Endocrine Therapy for Treatment of HER2 Positive Metastatic Breast Cancer

Active, not recruiting
2
19
US
Anastrozole, Anastrazole, Arimidex, ICI D1033, ICI-D1033, ZD-1033, Denifanstat, ASC 40, ASC-40, ASC40, FASN Inhibitor TVB-2640, TVB 2640, TVB-2640, TVB2640, Exemestane, Aromasin, FCE-24304, Fulvestrant, Faslodex, Faslodex(ICI 182,780), ICI 182,780, ICI 182780, ZD9238, Echocardiography, EC, Letrozole, CGS 20267, Femara, Paclitaxel, Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, Trastuzumab, 180288-69-1, ABP 980, ALT02, Biceltis, CANMab, CT-P06, CT-P6, Herceptin, Herceptin Biosimilar PF-05280014, Herceptin Trastuzumab Biosimilar PF-05280014, Herclon, Hertraz, Herzuma, Immunoglobulin G 1 (Human-Mouse Monoclonal RhuMab HER2gamma1-Chain Antihuman p185(Sup c-erbB2) Receptor), Disulfide with Human-Mouse Monoclonal RhuMab HER2 Light Chain, Dimer, Kanjinti, Ogivri, Ontruzant, PF-05280014, QL 1701, QL-1701, QL1701, rhuMAb HER2, RO0452317, SB3, Trastuzumab Biosimilar ABP 980, Trastuzumab Biosimilar ALT02, Trastuzumab Biosimilar CT-P6, trastuzumab biosimilar EG12014, Trastuzumab Biosimilar HLX02, Trastuzumab Biosimilar PF-05280014, Trastuzumab Biosimilar QL1701, Trastuzumab Biosimilar SB3, Trastuzumab Biosimilar SIBP-01, Trastuzumab-anns, Trastuzumab-dkst, Trastuzumab-dttb, Trastuzumab-pkrb, Trastuzumab-qyyp, Trazimera, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, computerized axial tomography, Computerized axial tomography (procedure), Computerized Tomography, CT, CT SCAN, tomography, Magnetic Resonance Imaging, MRI, Magnetic Resonance, Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI Scan, MRIs, NMRI, nuclear magnetic resonance imaging, sMRI, Structural MRI, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Biopsy, BIOPSY_TYPE, Bx
Mayo Clinic, National Cancer Institute (NCI)
Advanced Breast Carcinoma, HER2-Positive Breast Carcinoma, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, HER2-positive Breast Cancer
07/24
12/25
NCT05835180: A Phase I Pharmacokinetic Study of TVB-2640 (Denifanstat) in Subjects With Mild, Moderate, or Severe Hepatic Impairment Compared to Subjects With Normal Hepatic Function

Completed
1
48
Europe, US
TVB-2640 - 50 mg
Sagimet Biosciences Inc.
Non-alcoholic Steatohepatitis, Hepatic Impairment, Cirrhosis
12/23
12/23
MCC-16-MULTI-22, NCT02980029: TVB 2640 for Resectable Colon Cancer Other Resectable Cancers; a Window Trial.

Terminated
1
23
US
TVB-2640, Placebo
Mark Evers, National Cancer Institute (NCI)
Colon Cancer
10/23
10/23
NCT05743621: Study of TVB-2640 in Men With Metastatic Castration-Resistant Prostate Cancer

Recruiting
1
30
US
TVB-2640, Enzalutamide, Xtandi
Weill Medical College of Cornell University, Sagimet Biosciences Inc.
Prostatic Neoplasms, Castration-Resistant
11/25
11/26
TVB-3567 / Sagimet Biosci, Ascletis
NCT06989840: Phase 1 Study to Evaluate the Safety, Tolerability, PK, and PD of TVB-3567 in Healthy Participants With or Without Acne

Recruiting
1
128
US
TVB-3567, Placebo
Sagimet Biosciences Inc.
Acne
12/25
01/26
Enweida (envafolimab) / 3DMed, Ascletis
ChiCTR2200060332: Concurrent chemoradiotherapy with or without recombinant human endostatin (Endo) consolidation with envafolimab in patients with stage III unresectable non-small cell lung cancer (NSCLC)

Not yet recruiting
4
72
 
The dose of Endostar is 7.5 mg/m2, continuous intravenous infusion 5 days a week, starting 5 days before radiotherapy, one cycle every 2 weeks, a total of 4 cycles. Synchronous EP program for 3 cycles. Consolidation therapy with enverolimab was started 14 days to 30 days after the end of radiotherap ;3 cycles of radiotherapy synchronous EP program. 14 days to 30 days after the end of radiotherapy, Envolimumab consolidation therapy was started, 400 mg each time, 28 days/time, until disease progression or intolerance, and the longest treatment time was 1 year.
Jiamusi Cancer Hospital; Jiamusi Cancer Hospital, China International Medical Foundation
Stage III unresectable non-small cell lung cancer
 
 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Pegasys (pegylated interferon α -2a) / Pharma& Schweiz
ACTRN12608000400369: A single-arm, open-label, pilot study evaluating the efficacy and safety of directly observed peginterferon alfa-2a with ribavirin in conjunction with a peer counsellor in patients actively using injecting drugs who have chronic hepatitis C and attend a drug and alcohol centre.

Recruiting
4
50
 
Dr Joe Sasadeusz, Roche Products Pty Ltd
Impact of standard pharmacotherapy treatment of chronic Hepatitis C virus (HCV) infection on: (i) quality of life, (ii) mental health status, (iii) injecting drug behaviours, and (iv) opioid pharmacotherapy use in active injecting drug users (IDUs)., Side effects related to chronic Hepatitis C virus (HCV) infection and treatment in active injecting drug users (IDUs)., Factors affecting compliance of active injecting drug users (IDUs) for standard pharmacotherapy treatment of chronic Hepatitis C virus (HCV) infection., Chronic hepatitis C virus (HCV) infection.
 
 
ChiCTR-ONRC-05000623: Treatment with Peginterferon Alfa-2a (40 KD) (PEGASYS?) of Chronic Hepatitis B Patients, Who Have Failed Anti-Viral Treatment? A Pilot Study

Completed
4
98
 
Peginterferon Alfa-2a (40 KD) (PEGASYS?) 180 mcq per week for 48 weeks versus placebo ;Peginterferon Alfa-2a (40 KD) (PEGASYS?) 180 mcq per week for 48 weeks versus placebo
Roche Hong Kong Limited; Level of the institution:, Hepatitis Research Fund
Viral Diseases
 
 
ChiCTR2000030000: An open, controlled clinical trial for evaluation of ganovo combined with ritonavir and integrated traditional Chinese and Western medicine in the treatment of novel coronavirus infection (COVID-19)

Recruiting
4
50
 
Ganovo/ ritonavir oral ;Pegasys injection ;Novaferon intramuscular injection+Spray inhalation ;Coriolus oral ;TCM+Spray inhalation
Nanchang Ninth Hospital; Nanchang Ninth Hospital, Ascletis Pharmaceuticals CO., LTD.
Pneumonia caused by new coronavirus
 
 
ChiCTR-TRC-10000770: Research of Combination Therapy of Western and Traditional Chinese Medicine on Chronic Hepatitis C

Completed
4
740
 
Binggan Granule 1, 1# bid for 12 months ;Pegasys 180ug qw+Ribavirin 300mg tid+Binggan Granule 2, 1# bid for 12 months ;Binggan Granule 2, 1# bid for 12 months ;Pegasys 180ug qw+Ribavirin 300mg tid+Binggan Granule 1, 1# bid for 12 months
Shuguang Hospital Affiliated to Shanghai Univercity of Traditional Chinese Medicine; Level of the institution:, Ministry of Health, China
Chronic hepatitis C
 
 
2010-023245-30: Treatment with Peg-interferon alfa-2a and ribavirin in patients with hepatitis HCV-related, with or without HIV co-infection, and end stage renal disease on dialysis

Ongoing
4
20
Europe
Tablet, Solution for injection, COPEGUS*168CPR RIV 200MG, PEGASYS*SC SIR 0,5ML 180MCG+AG
ISTITUTO NAZIONALE DELLE MALATTIE INFETTIVE LAZZARO SPALLANZANI
Chonic hepatitis HCV-related
 
 
NCT01006512: Peginterferon Plus Ribavirin for Hepatitis C Patients Concomitant With Malignancy Other Than Hepatocellular Carcinoma

Recruiting
4
120
RoW
Peginterferon alfa-2a plus ribavirin, pegasys
Kaohsiung Medical University
Chronic Hepatitis C, Neoplasms
06/11
06/11
ChiCTR-TRC-10000926: A phase IV study on optimizing Pegasys plus Ribavirin treatment in difficult-to-treat Chronic Hepatitis C treatment naive patients.

Completed
4
440
 
The subjects who meet EVR will be treated as follows: Pegasys 180μg/wk plus Ribavirin 10.6-15mg/kg/day for totally 48 weeks. ;The rest patients who fail to reach EVR will be randomized (1:1) into 2 study arms as follows: Pegasys 180μg/wk plus Ribavirin 10.6-15mg/kg/day for totally 72 weeks. ;The rest patients who fail to reach EVR will be randomized (1:1) into 2 study arms as follows: Pegasys 180μg/wk plus Ribavirin 10.6-15mg/kg/day for totally 96 weeks
Peking University People's Hospital; Ministry of Health, National S&T Major Project for Infectious Diseases Control
chronic hepatitis C
 
 
ChiCTR-TRC-10000915: A phase IV study on optimizing Pegasys plus Ribavirin in the treatment of non-respond Chronic Hepatitis C patients

Completed
4
100
 
Pegasys 180ug/wk plus Ribavirin 10.6-15mg/kg/day for 72 weeks ;Pegasys 180ug/wk plus Ribavirin 10.6-15mg/kg/day for 96 weeks
Peking University People's Hospital; Ministry of Health, National S&T Major Project for Infectious Diseases Control
chronic hepatitis C
 
 
ChiCTR-TRC-10000916: A phase IV study on optimizing Pegasys plus Ribavirin for paitents with relapse chronic Hepatitis C

Completed
4
132
 
Pegasys 180μg/wk plus Ribavirin 10.6-15mg/kg/day for 48 weeks ;Pegasys 180μg/wk plus Ribavirin 10.6-15mg/kg/day for 72 weeks
Peking University People's Hospital; Ministry of Health, National S&T Key Project for Infectious Diseases Control
Chronic hepatitis C
 
 
ChiCTR-RNRC-10001089: A study on optimizing Pegasys or Peg IFN alpha-2b plus Ribavirin in the treatment of non-responsive Chronic Hepatitis C patients

Completed
4
100
 
Peg IFN alpha-2a is replaced by Peg IFNalpha-2b, Peg IFN alpha-2b 1.0-1.5ug/kg/wk plus Ribavirin 10.6-15mg/kg/day for 44 weeks after serum HCV RNA negative during 72-96 weeks ;PegIFN alpha-2a is replaced by PegIFNalpha-2b: PegIFNalpha-2b 1.0-1.5ug/kg/wk plus Ribavirin 10.6-15mg/kg/day for 72-96 weeks. Stop the medication if serum HCV RNA does not turn negative
3rd Hospital of HeiBei Medical University; Level of the institution:, Hebei Science and Technology Bureau
chronic hepatitis C
 
 
ChiCTR-TRC-09000612: Efficacy and safety of Pegasys combined with adefovir in the treatment of chronic hepatitis B with HBeAg(+)

Completed
4
120
 
Pegasys ;Pegasys combined with adefovir
Third Hospital Affiliated to Zhongshan University; Level of the institution:, Self-financing
Chronic hepatitis B with HBeAg(+).
 
 
ChiCTR-TRC-10001107: A phase IV study on optimizing Pegasys or Recombinant Human Interferonα2a pius Ribavirin for patients with relapse chronic Hepatitis C

Completed
4
132
 
PegIFN alpha-2a changed with Peg IFN alpha-2b , PegIFN alpha-2b 1.0-1.5ug/kg/wk, plus Ribavirin 10.6-15mg/kg/day for 44 weeks after serum HCV RNA negative during 72-96 weeks ;PegIFN alpha-2a changed with PegIFN alpha-2b, PegIFN alpha-2b 1.0-1.5ug/kg/wk, plus Ribavirin 10.6-15mg/kg/day for 72-96 weeks without serum HCV RNA negative, then, PegIFN alpha-2b and Ribavirin were stopped
The Third Hospital of Hebei Medical University; Hebei Science and Technology Bureau, Hebei Science and Technology Bureau
chronic hepatitis C
 
 
ChiCTR-TRC-10001090: A study on optimizing Pegasys or Recombinant Human Interferon α-2b plus Ribavirin in treatment of na?ve patients with chronic hepatitis C.

Completed
4
260
 
The subjects will be treated as follows: Pegasys 180ug/wk plus Ribavirin 10.6-15mg/kg/day for 44 weeks after HCV RNA undetectable/clearance ;The rest patients will be treated as follows: IFNα-2b 500MU/2 days plus Ribavirin 10.6-15mg/kg/day for 44 weeks after HCV RNA undetectable /clearance
Third Hospital of HeiBei Medical University; Hebei Science and Technology Bureau, Hebei Science and Technology Bureau
chronic hepatitis C
 
 
2014-005388-34: Single arm prospective clinical study to evaluate the efficacy of combination therapy sofosbuvir+ribavirin+peg-interferon in experienced patients with HCV-GT1 Studio clinico prospettico a braccio singolo di fase IV per la valutazione dell’efficacia e della sicurezza della terapia combinata Sofosbuvir + Ribavirina + Interferone Peghilato in pazienti con epatite cronica da HCV GT1 che hanno già fallito un precedente ciclo di duplice terapia con Ribavirina + Interferone Peghilato

Ongoing
4
120
Europe
SOVALDI, PEGASYS, RIBAVIRINA, 34459014, Film-coated tablet, Solution for injection, Capsule, hard, SOVALDI - 400 MG - COMPRESSA RIVESTITA CON FILM - FLACONE (HDPE) - 28 COMPRESSE, PEGASYS - 180MCG-SOLUZ. INIETTABILE-USO SOTTOCUT.-PENNA PRERIEMPITA-0.5 ML (360MCG/ML) 12 PENNE PRERIEMPITE, REBETOL - 200 MG 84 CAPSULE RIGIDE IN BLISTER
AZIENDA OSPEDALIERA DI PADOVA, GILEAD SCIENCE S.R.L. - Italia
chronic hepatitis HCV GT1 who have already failed a prior course of dual therapy with pegylated interferon + ribavirin epatite cronica da HCV GT1 che hanno già fallito un precedente ciclo di duplice terapia con Ribavirina + Interferone Peghilato, chronic hepatitis HCV GT1 already treated epatite cronica da HCV GT1 già trattati, Diseases [C] - Virus Diseases [C02]
 
 
2015-003024-31: Protecting immune responses in patients treated with the new DAA anti hepatitis C alone or in combination with previously used medications (interferon and ribavirin) Risposte immunitarie proteggenti in pazienti trattati con i nuovi farmaci anti epatite C (nuovi DAA) da soli o in associazione con i farmaci precedentemente utilizzati (interferone e ribavirina)

Not yet recruiting
4
30
Europe
PEGINTERFERONE ALFA-2A, RIBAVIRINA, SOFOSBUVIR, LEDIPASVIR+SOFOSBUVIR, N.A., Solution for injection, Capsule, hard, Film-coated tablet, PEGASYS - 180MCG-SOLUZ. INIETTABILE-USO SOTTOCUT.-PENNA PRERIEMPITA-0.5 ML (360MCG/ML) 1 PENNA PRERIEMPITA, REBETOL - 200 MG 84 CAPSULE RIGIDE IN BLISTER, SOVALDI - 400 MG - COMPRESSA RIVESTITA CON FILM - FLACONE (HDPE) - 28 COMPRESSE, HARVONI - 90 MG/400 MG - COMPRESSE RIVESTITE CON FILM - USO ORALE - FLACONE (HDPE) - 28 COMPRESSE RIVESTITE CON FILM
AZIENDA OSPEDALIERO-UNIVERSITARIA DI PARMA, GILEAD SCIENCES SRL
CHRONIC HEPATITIS C EPATITE C CRONICA, CHRONIC HEPATITIS C EPATITE C CRONICA, Diseases [C] - Virus Diseases [C02]
 
 
2004-005112-83: RANDOMISED CONTROLLED STUDY ON EARLY RESPONSE TO COMBINED ANTIVIRAL THERAPY IN CHRONIC EPATITES C PATIENT GENOTIPE 1 AND 4 WITH HCV RNA NEGATIVE WEEK 6

Ongoing
4
100
Europe
PEGASYS, COPEGUS*168CPR RIV 200MG, PEGASYS, COPEGUS*168CPR RIV 200MG
AZIENDA SANITARIA OSPEDALIERA S. GIOVANNI BATTISTA DI TORINO
SOSTAINED BIOCHEMICAL AND VIROLOGICAL RESPONSE TO COMBINATED THERAPY PEGILATED RIBAVIRIN IN CHRONIC EPATITIES PATIENTS G 1 AND 4
 
 
2005-002452-17: Pilot, open, multicenter, phase IV Clinical Trial to evaluate safety and efficacy in treatment with peginterferon alfa-2a plus ribavirin in VIH patients with advanced immunosupression and chronic hepatopathy secondary to hepatitis C virus.

Ongoing
4
30
Europe
peginterferon alfa 2a, ribavirin, peginterferon alfa 2a, ribavirin, Pegasys 180 microgrames, Pegasys 135 microgrames, Copegus 200 mg, Pegasys 180 microgrames, Pegasys 135 microgrames, Copegus 200 mg
Hospital Universitario de Valme
¨Hepatitis C Crónica
 
 
2005-005650-41: A Comparative, Randomized, Open-label, Multicenter Study, of Directly Observed Treatment of Chronic Hepatitis C (DOT) and auto administrated treatment with Copegus® (Ro 20-9963) and Pegasys® (Ro 25-8310).

Ongoing
4
156
Europe
Pegasys, Copegus, Ro 25-8310, Ro 20-9963, Pegasys, Copegus, Pegasys, Copegus
SESP
Chronic Hepatitis C
 
 
2006-001243-55: Open, multicenter, phase IV study to evaluate the safety and effectiveness of peginterferon alfa-2a (40 KD) associated with ribavirin for the treatment chronic hepatitis C with persistent normal ALT in HIV coinfected patients

Ongoing
4
230
Europe
Pegasys, Copegus, Pegasys, Copegus, Pegasys, Copegus
Miguel Santin Cerezales
Comparate the safety and effectivenes of the treatment with peginterferon alfa-2a in combination with ribavirin between HIV/HCV coinfected patients with persistent normal ALT levels versus HIV/HCV coinfected patients with high ALT levels
 
 
2007-002743-24: Study to evaluate different duration of treatment regimes of 40kD pegylated interferon alfa 2a (Pegasys) plus ribavirin on sustained virological responses (SVR) in Genotype 3 HCV infected cirrhotic patients

Ongoing
4
140
Europe
Pegasys, Copegus, Pegasys, Copegus, Pegasys, Copegus
Queen Mary University of London
Chronic hepatitis C infection with genotype 3 and advanced fibrosis
 
 
2007-001122-27: Tailored treatment of hepatitis C genotype 1

Ongoing
4
100
Europe
Pegasys, Copegus, Ro25-8310/V01, R20-9963/J10, Pegasys, Copegus, Pegasys, Copegus
Västra Götalandsregionen
Chronic infection with hepatitis C virus, genotype 1, with signs of liver inflammation.
 
 
2007-007075-16: The effect of peroxisome proliferator activator receptor γ agonist pre-treatment on pegylated interferon-α2a and ribavirin efficacy in hepatitis C patients, previously resistant to treatment with pegylated interferon and ribavirin - a randomized-controlled trial -

Ongoing
4
50
Europe
Copegus, Actos, Pegasys, Actos, Pegasys
VU university medical center
Chronic hepatitis C infection
 
 
2009-012459-96: VALORACIÓN INTENSIVA DE LA CINÉTICA DEL RNA DEL VIRUS DE LA HEPATITIS C COMO PREDICTOR PRECOZ DE AUSENCIA DE RESPUESTA VIROLÓGICA SOSTENIDA EN PACIENTES CON HEPATITIS CRÓNICA POR VHC TRATADOS CON INTERFERON PEGILADO Y RIBAVIRINA

Ongoing
4
100
Europe
pegintron, ribavirina, PEGASYS, 180 microgramos, solución inyectable en jeringa precargada, PEGINTRON 150 microgramos polvo y disolvente para solución inyectable en pluma precargada, REBETOL 200 mg cápsulas duras, PEGASYS, 180 microgramos, solución inyectable en jeringa precargada, PEGINTRON 150 microgramos polvo y disolvente para solución inyectable en pluma precargada, REBETOL 200 mg cápsulas duras
Dr Calleja Panero
HEPATITIS C
 
 
ChiCTR-PPC-15006199: A Multi-center, Randomized, Controlled Clinical Trial of Pegylated interferon alpha-2a (40KD) Plus Ribavirin With or Without Vitamin D in Chronic Hepatitis C

Not yet recruiting
4
224
 
vitamin D supplementation with pegylated interferon + ribavirin (PegIFN/RBV) ;pegylated interferon + ribavirin (PegIFN/RBV)
The First Affiliated Hospital of Xinjiang Medical University; The First Affiliated Hospital of Xinjiang Medical University, Switzerland's Roche
Chronic hepatitis C
 
 
NCT03013556: Study on an Optimal Antiviral Treatment in HBeAg Positive Chronic Hepatitis B Patients

Recruiting
4
180
RoW
Group A, TDF, tenofovir, Group B:TDF then TDF and Peginterferon alfa-2a, tenofovir,pegasys, Group C:TDF and Peginterferon alfa-2a then TDF
Ruijin Hospital
Chronic Hepatitis
12/21
12/21
NCT03084250: The Investigation of Peginterferon Alfa-2a on Optimal in Chronic Hepatitis B Patients Who Have a High Risk of HCC

Active, not recruiting
4
150
RoW
Peginterferon Alfa-2A, Pegasys, Adefovir, entecavir,tenofovir, either of them
Shanghai Nanhui Nanhua Hospital
Hepatitis B
04/23
12/23
2011-001919-31: DALIAH A Danish Study of Low-dose Interferon Alpha Versus Hydroxyurea in the Treatment of Ph-negative Chronic Myeloid Neoplasias - A National Randomized Prospective Study With Focus on Efficacy, Toxicity and Quality of Life DALIAH Dansk Studie af Lav-dosis Interferon Alpha vs Hydroxyurea i Behandlingen af Ph-Negative kroniske myeloproliferative neoplasier “Et Nationalt Randomiseret Prospektivt Kvalitetssikringsstudie med Særlig Fokus på Effekt, Toxicitet og Livskvalitet”

Ongoing
3
200
Europe
Suspension for injection in pre-filled pen, Capsule, hard, Pegasys, PegIntron, Hydrea
Roskilde sygehus, Swedish Orphan, Ellen og Aage Fausbølls Helsefond af 1975, Fonden til lægevidenskabens Fremme, Odense Universitetshospitals forskningspulje, Region Sjællands og Region Syddanmarks fælles forskningspulje
Chronic myeloid neoplasms Essential thrombocythemia Polycythemia vera primary myelofibrosis Kroniske myeloide neoplasier Essential thrombocythemia Polycythemia vera primary myelofibrosis, Chronic myeloid neoplasms Essential thrombocythemia Polycythemia vera primary myelofibrosis Kroniske myeloide neoplasier Essential thrombocythemia Polycythemia vera primary myelofibrosis, Diseases [C] - Blood and lymphatic diseases [C15]
 
 
NCT01727323 / 2010-021337-31: A Study to Assess the Safety, Tolerability and Efficacy of TMC435 Along With Pegylated Interferon Alpha-2a (Pegasys) and Ribavirin (Copegus) Triple Therapy in Chronic Hepatitis C Genotype-1 Infected Patients Co-infected With Human Immunodeficiency Virus-Type 1

Active, not recruiting
3
109
US, Canada, Europe
TMC435, Pegylated interferon alpha-2a, Ribavirin
Janssen Research & Development, LLC, Janssen R&D Ireland, Tibotec Pharmaceuticals
Hepatitis C Virus Genotype-1
08/13
08/13
2014-000453-37: Treatment with association of two drugs (Viread and Pegasys) in patients with hepatitis B. TRATTAMENTO CON ASSOCIAZIONE DI DUE FARMACI (VIREAD E PEGASYS) NEI PAZIENTI AFFETTI DA EPATITE B

Ongoing
3
80
Europe
Viread, Pegasys, Tablet, Solution for injection, Viread, Pegasys
Azienda Ospedaliera di Padova, Azienda Ospedaliera di Padova
Hepatitis B virus (HBV) EPATITE CRONICA HBV-CORRELATA, Chronic liver disease caused by hepatitis B MALATTIA EPATICA CRONICA CAUSATA DAL VIRUS DELL’EPATITE B, Diseases [C] - Virus Diseases [C02]
 
 
2004-001622-24: Phase III,multicentre,open-label,prospective randomised trial comparing Imatinib alone at 400mg versus 800mg daily versus Imatinib 400mg daily plus PEG Interferon-alpha with newly diagnosed chronic myeloid leukaemia

Ongoing
3
50
Europe
Glivec, Pegasys, Glivec (400mg), Glivec (800mg), Pegasys, Glivec (400mg), Glivec (800mg), Pegasys
Newcastle Hospital Trust
Chronic Myeloid Leukaemia (Chronic Phase)
 
 
2006-000853-23: Prospektivní, otevřená, randomizovaná multicentrická studie hodnotící účinnost a bezpečnost pegylovaného interferonu alfa 2a (Pegasys) v adjuvantní léčbě rizikového primárního kožního melanomu

Ongoing
3
252
Europe
Pegasys 180 mikrogramů, Roferon®-A, EU/1/02/221/008, 44/396/96-C, 44/160/99-C, 44/161/99-C, 44/086/02-C,
Kožní ordinace
Chirurgicky adekvátně odstraněný a histologicky verifikovaný primární kožní melanom ve stadiu IIB až IIIB podle nové AJCC 2003 klasifikace.
 
 
2006-006042-33: A pilot, open label, multicenter, randomized clinical trial on Lopinavir/Ritonavir-monotherapy vs Lopinavir/Ritonavir plus selected Nucs, in HIV/HCV coinfected patients with chronic hepatitis C or compensated cirrhosis, starting treatment with Ribavirin and Pegylated Interferon

Ongoing
3
50
Europe
KALETRA, COPEGUS, PEGASYS, KALETRA, COPEGUS, PEGASYS
OSPEDALE S. RAFFAELE
patients affected by HIV and chronic HCV or compensated cirrhosis
 
 
2006-005996-17: A pilot, open label, multicenter, randomized clinical trial on Lopinavir/ritonavir-monotherapy vs Lopinavir/ritonavir plus selected Nucs, in HIV/HCV ARV-naive coinfected patients with chronic hepatitis C or compensated cirrhosis, starting treatment with Ribavirin and Pegylated Interferonヤ

Ongoing
3
60
Europe
KALETRA, PEGASYS, COPEGUS, KALETRA, PEGASYS, COPEGUS
OSPEDALE S. RAFFAELE
PATIENTS AFFECTED BY HIV/HCV NAIVES FROM THERAPIES
 
 
2005-003648-70: Randomised, double-blinded phase IIIb study to optimise antiviral therapy response of a standard therapy consisting of peginterferon-alfa-2a and ribavirin plus the additional use of bezafibrat 400 mg/d in untreated patients with chronic hepatits C typ 1.

Ongoing
3
414
Europe
Cedur retard, Pegasys, Copegus, Cedur retard, Pegasys, Copegus
Charité Universitätsmedizin Berlin
First time treatment in chronic hepatitis C-infection patients with elevated GGT-level without coinfections as HBV, HDV and HIV
 
 
2006-006985-41: Estudio piloto en fase III, mutlicéntrico, aleatorizado, controlado y abierto, sobre la eficacia de Interferón Pegilado alfa-2a a dosis de 90 mcg semanal en retrasar la aparición del primer evento de descompensación hepática en pacientes con cirrosis hepática por virus C nunca descompensada y con coinfección por VIH, en los que el tratamiento estándar con Interferón Pegilado ha fracasado. Estudio IRISH.

Ongoing
3
220
Europe
PEGASYS (PEGINTERFERON ALFA-2A), PEGASYS (PEGINTERFERON ALFA-2A)
JOAQUIN PORTILLA
PACIENTES CON CIRROSIS HEPATICA (CH) POR VIRUS C NUNCA DESCOMPENSADA Y COINFECTADOS POR EL VIH QUE NO HAN RESPONDIDO AL TRATAMIENTO ESTANDAR CON INTERFERON PEGILADO Y RIBAVIRINA
 
 
2008-006453-40: Peg-INF alfa-2a plus ribavirin treatment of liver transplant patients with hepatitis C relaps on protocol liver biopsies - a Nordic study on rapid viral response, early viral response, end of treatment response and sustained viral response rates

Ongoing
3
100
Europe
Pegasys, Copegus, Pegasys 180 mcg / 135 mcg, Copegus 200 mg / 400 mg, Pegasys 180 mcg / 135 mcg, Copegus 200 mg / 400 mg
Karolinska University hospital Huddinge
Chronic hepatitis C infection
 
 
2009-018146-38: Multicenter randomized controlled study comparing the efficacy and safety of natural Multi-subtype interferon alpha (Multiferon) in association with ribavirin versus retreatment with pegylated interferon-alpha 2a and ribavirin in non-responding genotype 1 hepatitis C patients.

Ongoing
3
110
Europe
Multiferon, Pegasys, Copegus, Multiferon, Pegasys, Copegus
Swedish Orphan International AB
Hepatitis C
 
 
2010-019501-41: A randomized study comparing two drugs: hydroxyurea and Pegylated Interferon Alfa-2a, in an open label clinical trial in two independent diseases: (1) high risk polycythaemia vera and (2) high risk essential thrombocythaemia.

Ongoing
3
95
Europe
peginterferon alfa-2a, Hydroxyurea, Pegasys, Pegasys, Hydroxyurea, Pegasys, Hydroxyurea
CONSORZIO MARIO NEGRI SUD, Consorzio Mario Negri Sud, Myeloproliferative Disease Research Consortium (MPD-RC), Myeloproliferative Disorders Research Consortium, National Cancer Institute, F.Hoffmann-La Roche, Cancer Research UK, MPD-RC
The myeloproliferative disorders essential thrombocythaemia (ET) and polycythaemia vera (PV).
 
 
NCT01369212: Combination Therapy of Pegylated Interferon Alfa-2a and Tenofovir Versus Tenofovir Monotherapy in Chronic Hepatitis B

Completed
3
201
Canada, US
Tenofovir, Hepatitis B, Viread, Peginterferon-alfa 2a and tenofovir, PEGASYS, tenofovir
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), University of Pittsburgh, National Center for Research Resources (NCRR)
Hepatitis B
03/21
03/21
D-LIVR, NCT03719313 / 2018-003167-54: Study of the Efficacy and Safety of Lonafarnib / Ritonavir With and Without Pegylated Interferon -Alfa-2a

Completed
3
407
Europe, Canada, US, RoW
Lonafarnib, EBP994, Sarasar, LNF, Ritonavir, Norvir, RTV, PEG IFN-alfa-2a, Pegasys, pegylated interferon-alfa, Placebo Lonafarnib, Placebo Ritonavir
Eiger BioPharmaceuticals
Hepatitis Delta Virus
10/22
03/23
ACTRN12605000041651: Phase II trial of Pegasys in Glivec responsive chronic phase chronic myeloid leukaemia

Completed
2
60
 
Australasian Leukaemia and Lymphoma Group, Novartis Australia, Roche Australi
Chronic myeloid leukaemia
 
 
2010-019500-23: Therapy with Pegylated Interferon Alfa-2a for Patients with Polycythemia Vera or Essential Thrombocythemia who are Either Hydroxyurea Resistant or Intolerant Or have had Abdominal Vein Thrombosis. Terapia con l'interferone Alfa-2a (PEGASYS) Peghilato per i pazienti con Policitemia Vera o Trombocitemia Essenziale che sono resistenti o intolleranti al trattamento con Hydroxyurea o che hanno avuto una trombosi della vena spalcnica.

Ongoing
2
188
Europe
Solution for injection, Peginterferon PFS
CONSORZIO MARIO NEGRI SUD, Myeloproliferative Disorders-Research Consortium
High risk polycythemia vera and high risk essential thrombocythemia Policitemia Vera (PV) ad alto rischio o Trombocitemia Essenziale (ET) ad alto rischio, polycythemia vera or essential thrombocythemia Policitemia Vera o Tromcitemia Essenziale, Diseases [C] - Blood and lymphatic diseases [C15]
 
 
2014-003894-41: Effect of Interferon on protecting immune response in chronic hepatitis B patients under treatment for the infection with standard antiviral therapy Effetto dell’Interferone sulla risposta immunitaria proteggente in pazienti con epatite B cronica già in trattamento per l’infezione con terapia antivirale standard

Ongoing
2
80
Europe
Peginterferone alfa-2a, Entecavir, Tenofovir Disoproxil, Solution for injection in pre-filled syringe, Tablet, Pegasys, Baraclude, Viread
Azienda Ospedaliero-Universitaria di Parma, F. Hoffmann - La Roche Ltd, Gilead Sciences srl, Regione Emilia-Romagna
Chronic hepatitis B infection Infezione da Epatite B cronica, Chronic hepatitis B infection Infezione da Epatite B cronica, Diseases [C] - Virus Diseases [C02]
 
 
2014-000815-15: add-on therapy of HBV chronic infection Terapia di associazione sequenziale della epatite B cronica

Ongoing
2
40
Europe
pegylated interferon alpha 2a, Suspension for injection in pre-filled pen, Pegasys
Azienda Ospedaliera, Polo Universitario Luigi Sacco, Milano, Università degli Studi di Milano
Chronic hepatitis B Epatite B cronica, Chronic Hepatitis B epatite B cronica, Diseases [C] - Virus Diseases [C02]
 
 
2013-003295-12: Kombinationsbehandling med Interferon og JAK1-2 Hæmmer i behandlingen af Ph-Negativ Myeloprolifertiv Cancer

Ongoing
2
50
Europe
Jakavi, Jakavi, Pegasys 135 microgram, PegIntron 50 microgram, Jakavi, Pegasys 135 microgram, PegIntron 50 microgram
Roskilde University Hospital, Novartis
Polycythemia vera Hyperproliferativ myelofibrosis, Diseases [C] - Blood and lymphatic diseases [C15]
 
 
2016-001010-17: Treatment withdrawal in patients with hepatitis B virus infection to promote clearance of the virus from the body

Ongoing
2
240
Europe
Peginterferon alfa-2a, Solution for injection in pre-filled syringe, Pegasys
Imperial College, London, NIHR EME
Hepatitis B viral infection, Hepatitis B viral infection, Diseases [C] - Virus Diseases [C02]
 
 
2017-001647-12: A study to determine how safe the treatment is for subjects diagnosed with hepatitis B virus infections when combined with other treatments for hepatitis B. Subjects must have no evidence of liver damage. Un estudio para determinar la seguridad del tratamiento para los sujetos diagnosticados con infecciones por el virus de la hepatitis B cuando se combinan con otros tratamientos para la hepatitis B. Los sujetos no deben tener evidencia de daño hepático.

Ongoing
2
20
Europe
ARB-001467, Viread, Pegasys, ARB-001467, Solution for infusion, Film-coated tablet, Solution for injection in pre-filled syringe, Viread, Pegasys
Arbutus Biopharma Corporation, Arbutus Bipoharma Corporation
Hepatitis B virus e-antigen (HBeAg)-negative subjects with chronic hepatitis B virus infection (CHB) Pacientes con infección crónica por el virus de la hepatitis B (HBC) HBeAg-negativo sin cirrosis, Subjects infected with hepatitis B virus Los sujetos infectados con el virus de la hepatitis B, Diseases [C] - Virus Diseases [C02]
 
 
2018-004150-13: Combination Therapy with Interferon-Alpha2a and Ruxolitinibin Newly Diagnosed Patients with Polycythemia Vera.A Danish Safety and Efficacy Study.

Not yet recruiting
2
25
Europe
Tablet, Injection, Jakavi, Pegasys
Zealand University hospital, Novartis
Polycythemia Vera, Polycythemia Vera, Diseases [C] - Blood and lymphatic diseases [C15]
 
 
2019-001485-15: This study will use an investigational product (bulevirtide) for the treatment of chronic hepatitis Delta to learn the therapeutic effect, and safety of the drug in humans.

Ongoing
2
175
Europe
Bulevirtide, Lyophilisate for solution for injection, Solution for injection, Pegasys
MYR GmbH, MYR GmbH
Chronic Hepatitis Delta, Chronic Hepatitis Delta, Diseases [C] - Virus Diseases [C02]
 
 
2019-004978-26: A clinical study to evaluate efficacy, pharmacokinetics, safety, and tolerability of response-guided treatment with JNJ-73763989 + JNJ-56136379 + nucleos(t)ide analog regimen with or without pegylated interferon alpha-2a in treatment-naïve patients with HBeAg positive chronic hepatitis B virus infection.

Not yet recruiting
2
80
Europe
JNJ-73763989, JNJ-56136379, Solution for injection, Tablet, Film-coated tablet, Solution for injection in pre-filled syringe, Tenofovir disoproxil Mylan 245 mg film-coated tablets, Vemlidy 25 mg film-coated tablets, Pegasys 180 micrograms solution for injection in pre-filled syringe
Janssen-Cilag International NV, Janssen Sciences Ireland Unlimited Company
Chronic Hepatitis B Virus Infection, Chronic Hepatitis B Virus Infection, Diseases [C] - Virus Diseases [C02]
 
 
2021-002450-81: A Clinical Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of Treatment With JNJ-73763989, Nucleos(t)ide Analogs, and Pegylated Interferon Alpha-2a in Patients With Chronic Hepatitis B Virus Infection. Estudio clínico para evaluar la eficacia, seguridad, tolerabilidad y farmacocinética del tratamiento con JNJ-73763989, análogos de nucleos(t)ido e interferón pegilado alfa-2a en pacientes con infección crónica por el virus de la hepatitis B.

Ongoing
2
102
Europe
JNJ-73763989, Solution for injection, Film-coated tablet, Solution for injection in pre-filled syringe, Entecavir Mylan 0.5 mg film-coated tablets, Viread 245 mg film-coated tablets, Vemlidy 25 mg film-coated tablets, Pegasys 180 micrograms solution for injection in pre-filled syringe
Janssen-Cilag International NV, Janssen Research and Development LLC
Chronic Hepatitis B Virus Infection Infección crónica por el virus de la hepatitis B, Chronic Hepatitis B Virus Infection Infección crónica por el virus de la hepatitis B, Diseases [C] - Virus Diseases [C02]
 
 
2021-001033-39: A Phase 2 Study to Evaluate the Safety, Tolerability, and Efficacy of Regimens Containing VIR -2218, VIR-3434, and/or PEG-IFNα in Subjects with Chronic Hepatitis B Virus Infection

Not yet recruiting
2
260
Europe
Pegasys, VIR-2218, VIR-3434, NA, Solution for injection, Lyophilisate for solution for injection, Pegasys
Vir Biotechnology, Inc., Vir Biotechnology, Inc.
Chronic HBV infection., Chronic infection of Hepatitis B Virus., Diseases [C] - Immune System Diseases [C20]
 
 
SWITCH-1, NCT02583685: Switching Regimen in Treating Cirrhotic HCV GT1b Subjects

Completed
2
138
RoW
PR4 + LDV/SOF + ASV 4 wk, Pegasys®, Copegus®, Harvoni®, Sunvepra®, PR4 + LDV/SOF + SMV 4 wk, OLYSIO®, PR4 + LDV/SOF + ASV 6 wk, PR4 + LDV/SOF + SMV 6 wk, PR4 + LDV/SOF + ASV 8 wk, PR4 + LDV/SOF + SMV 8 wk, PR4 + LDV/SOF + ASV 12 wk, PR4 + LDV/SOF + SMV 12 wk
Humanity and Health Research Centre, Beijing 302 Hospital, Nanfang Hospital, Southern Medical University
Chronic Hepatitis C Infection
10/24
10/24
2020-003956-34: A Clinical Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of Treatment With JNJ-73763989, JNJ-56136379, Nucleos(t)ide Analogs, and Pegylated Interferon Alpha-2a in Virologically Suppressed Patients With Chronic Hepatitis B Virus Infection.

Not yet recruiting
2
50
Europe
JNJ-73763989, Solution for injection, Film-coated tablet, Solution for injection in pre-filled syringe, Viread 245 mg film-coated tablets, Vemlidy 25 mg film-coated tablets, Entecavir Mylan 0.5 mg film-coated tablets, Pegasys 180 micrograms solution for injection in pre-filled syringe
Janssen-Cilag International NV, Janssen Research and Development LLC
Chronic Hepatitis B Virus Infection, Chronic Hepatitis B Virus Infection, Diseases [C] - Virus Diseases [C02]
 
 
NCT04426968: A Phase II Study of Hepalatide in Subjects With Chronic Hepatitis B

Completed
2
96
RoW
Hepalatide 2.1mg, L47, Hepalatide 4.2mg, Hepalatide 6.3mg, placebo 2.1mg, placebo 4.2mg, placebo 6.3mg, Pegylated Interferon, Pegasys
Shanghai HEP Pharmaceutical Co., Ltd.
Hepatitis B, Chronic
11/23
11/23
NCT00452023: Pegasys® in Patients With Myeloproliferative Diseases

Completed
2
83
US
IFN-alpha2a, Pegylated-Interferon Alpha-2A, PEG-IFNa-2a, Pegasys
M.D. Anderson Cancer Center
Myeloproliferative Disorders
05/23
05/23
NCT05244057: A Study of Hepalatide Combined With TAF and PEG-IFN as Finite Treatment of Chronic Hepatitis B Patients

Completed
2
8
RoW
Hepalatide, L47, Placebo of Hepalatide, Placebo, Tenofovir Alafenamide Tablets, Vemlidy, Pegylated Interferon alfa 2a, Pegasys
Shanghai HEP Pharmaceutical Co., Ltd., Shanghai Tong Ren Hospital, Shanghai East Hospital
Chronic Hepatitis B
06/24
06/24
Piranga, NCT04225715 / 2019-002086-35: A Trial To Evaluate The Efficacy And Safety Of Multiple Combination Therapies In Participants With Chronic Hepatitis B

Completed
2
281
Europe, Canada, US, RoW
Nucleos(t)ide (NUC), CpAM (RO7049389), TLR7 (RO7020531), siRNA (RO7445482), PEG-IFN, Pegasys®, PD-L1 LNA (RO7191863)
Hoffmann-La Roche
Hepatitis B, Chronic
07/24
07/24
ALPHAGEM, NCT05941845: Interferon Alfa Therapy Based on Th17 Profile in Membranous Nephropathy

Not yet recruiting
2
5
Europe
Peginterferon Alfa-2A 180 MCG/ML Injectable Solution, Pegasys®, interferon alfa
Centre Hospitalier Universitaire de Nice
Membranous Nephropathy
01/25
07/25
IPOS, NCT04798612: Effect of Low-dose Interferon-alfa2a on Peri-operative Immune Suppression

Recruiting
2
68
Europe
Pegasys, Saline
Zealand University Hospital, University of Copenhagen
Colon Cancer
08/25
12/25
MoST-TAP, NCT06003621: Tiragolumab and Atezolizumab in Advanced Pan-cancer Patients

Recruiting
2
96
RoW
Tiragolumab, RO7092284, MTIG7192A, RG-6058, Anti-TIGIT, Atezolizumab, Tecentriq, MPDL3280A, RG7446, RO5541267
Omico, Hoffmann-La Roche, The George Institute for Global Health, Australia
Solid Tumor, Adult
05/26
11/28
FAIM, NCT04920708: Fulvestrant, Ipatasertib and CDK4/6 Inhibition in Metastatic ER+/HER2- Breast Cancer Patients Without ctDNA Suppression

Recruiting
2
324
Europe
Ipatasertib 300mg, RG7440, Fulvestrant 500g, Faslodex, Palbociclib 75mg-125mg, Ibrance, CDK4/6 Inhibitor, Abemaciclib / Ribociclib / Palbociclib
Royal Marsden NHS Foundation Trust, Pfizer, Hoffmann-La Roche
Metastatic Breast Cancer, ER+ Breast Cancer, Advanced Breast Cancer
09/26
09/26
ACTIVATE, NCT02471430: Reducing the Residual Reservoir of HIV-1 Infected Cells in Patients Receiving Antiretroviral Therapy

Completed
1/2
17
US
Panobinostat, Farydak, LBH589, Pegylated Interferon-alpha2a, Pegasys
Massachusetts General Hospital, Novartis, Genentech, Inc.
HIV Infection
08/22
12/23
NCT04943679: Anti-PD-1/PD-L1 Antibodies Plus Pegylated Interferon Alfa-2b Treatment in Patients With Advanced-Stage HCC

Recruiting
1/2
15
RoW
Anti-PD-1/PD-L1, PEG-Interferon Alfa, Pegasys
Shanghai Zhongshan Hospital
Hepatocellular Carcinoma
12/24
12/24
MORPHEUS BC, NCT04802759: A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer

Recruiting
1/2
316
Europe, US, RoW
Giredestrant, GDC-9545, RO7197597, RG6171, Abemaciclib, Verzenio™, Ipatasertib, GDC-0068, RO5532961, RG7440, Inavolisib, GDC-0077, RO7113755, RG6114, Ribociclib, Kisqali®, Everolimus, Afinitor®, Samuraciclib, ICEC0942, CT7001, PH FDC SC, Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf, PHESGO™, RO7198574, RG6264, Palbociclib, Ibrance®, Atezolizumab, Tecentriq®, RO5541267, RG7446
Hoffmann-La Roche
Inoperable, Locally Advanced or Metastatic, ER-positive Breast Cancer
11/27
11/27
ChiCTR-OPQ-14005299: Tolerance, pharmacokinetics and pharmacodynamics of PEG-INF-alpha 2b in healthly volunteers: A Randomized, Single center, drug control, Open-Label study

Recruiting
1
58
 
PegIntron subcutaneously ;PEGASYS subcutaneously ;hypodermic
West China Hospital, Sichuan University; West China Hospital, Sichuan University, ANHUI ANKE BIO TECNOLOGY(GROUP) CO.,LTD
Chronic hepatitis B and C
 
 
NCT06144697: A Study to Evaluate the Safety, Tolerability, Drug Levels, Food, Formulation, and pH Effects on Relative Absorption of BMS-986465 and Its Active Derivative BMS-986464 in Healthy Participants

Terminated
1
267
US
BMS-986465, Placebo, Pegasys, Famotidine
Bristol-Myers Squibb
Healthy Participants
10/24
10/24
NCT05729139: Cemiplimab/Peg-Interferon-α in Advanced CSCC

Withdrawn
1
21
US
Cemiplimab-Rwlc, Libtayo, PEG-IFN alfa-2a, PEGASYS
Baptist Health South Florida, Regeneron Pharmaceuticals
Cutaneous Squamous Cell Carcinoma, Squamous Cell Carcinoma, Advanced Squamous Cell Carcinoma
07/26
07/28
ChiCTR-TRC-12002116: A multi-center randomized controlled clinical trial on treatment of chronic hepatitis C using Vitamin D combine pegylated interferon + ribavirin

Completed
N/A
200
 
vitamin D + peg-INF-alpha-2a ;peg-INF-alpha-2a
Department of Infectious Deases of First Teaching Hospital of Xinjiang Medical University; Department of Infectious Deases of First Teaching Hospital of Xinjiang Medical University, Roche China (Shanghai)
Hepatitis C
 
 
AV-FLCHB, NCT06535048: Impact of Fatty Liver on Hepatitis B Therapy

Active, not recruiting
N/A
500
NA
Entecavir;Tenofovir Disoproxil Fumarate (TDF); Tenofovir alafenamide fumarate (TAF);Interferons, Entecavir: Baraclude, Tenofovir Disoproxil Fumarate (TDF): Viread, Tenofovir Alafenamide Fumarate (TAF): Vemlidy, Pegylated Interferon Alpha (Peg-IFN-α): Pegasys
Tianjin Second People's Hospital
Fatty Liver Disease, Chronic Hepatitis B, Antiviral Treatment
06/19
08/24
NCT03957629: Optimized Treatment of Peginterferon Alfa 2a in Treatment Experienced Patients With HBV Related Liver Fibrosis

Recruiting
N/A
186
RoW
Tenofovir Disoproxil Fumarate, Viread, Beixin, PEG-Interferon alfa 2a, Pegasys
Third Affiliated Hospital, Sun Yat-Sen University
Hepatitis B, Liver Fibrosis
07/21
07/23
RCAP, NCT05683548: Replicor Compassionate Access Program

No Longer Available
N/A
Europe, RoW
REP 2139-Mg, Tenofovir Disoproxil Fumarate, Viread, Pegylated interferon alpha2a, Pegasys
Replicor Inc.
Viral Hepatitis B, Viral Hepatitis D, Cirrhosis, Liver, Decompensated Cirrhosis, Ascites Hepatic, Varices, Esophageal, Hepatocellular Carcinoma
 
 
HERACLIS-BLV, NCT05928000: HEllenic Multicenter ReAl-life CLInical Study for Bulevirtide Therapy in Chronic Hepatitis D:

Recruiting
N/A
80
Europe
Bulevirtide, Entecavir, Tenofovir, Pegasys
University of Athens
Hepatitis D
11/23
12/23
NCT03771677: To Optimize the Therapeutic Pathway of Peginterferon Treatment in Patients With CHB Based on IFNA2p.Ala120Thr /ISGs.

Recruiting
N/A
400
RoW
Nucleotide Analog, Nucleotide Analogs, Interferon Alfa-2A, Pegasys
Sun Yat-sen University, First People's Hospital of Foshan, Eighth Affiliated Hospital, Sun Yat-sen University
Hepatitis B
12/23
12/24
Ganovo (danoprevir) / Roche, Ascletis, Pfizer
ChiCTR1800019812: The efficacy and safety of 12-week ritonavir-boosted danoprevir plus pegylated interferon and ribavirin treatment of CHC genotype 1 patients experienced DAA failure: a multi-center, open labeled clinical trial

Not yet recruiting
4
30
 
12 weeks treatment, 12weeks follow-up
the 2nd affiliated hospital of Chongqing Medical School; Ascletis Pharmaceuticals Co., Ltd., Response by Ascletis Pharmaceuticals Co.,Ltd
HCV
 
 
ChiCTR2000040851: The pharmacokinetics of single and multiple doses of ASC16 quadruplex administration

Completed
1
64
 
ASC16 (200 mg, 1 tablet) ;ASC08 (100 mg, 1tablet) ;RTV (100 mg, 1tablet) ;RBV (500 mg, 5tablet) ;ASC16 (200 mg, 1 tablet) +ASC08/ R (100 mg/100 mg, 1 tablet /1 tablet) + RBV (500 mg, 5 tablets) ;Group F: ASC16 (200 mg, 1 tablet, QD) + ASC08/ R (100 mg/100 mg, 1 tablet /1 tablet, BID) + RBV (500 mg, 5 tablets, BID)
Nanning Second People's Hospital; Ascletis BioScience Co., Ltd., self-finance
Basic Science
 
 
ChiCTR2000030259: Evaluation Danoprevir sodium tablets combined with ritonavir in the treatment of novel coronavirus pneumonia (COVID-19): a randomized, open and controlled trial

Recruiting
N/A
60
 
Danoprevir sodium tablets,/ritonavir oral ;Symptomatic treatment
Shanghai Changzheng Hospital; Shanghai Changzheng Hospital, Ascletis Pharmaceuticals CO., LTD.
Novel Coronavirus Pneumonia (COVID-19)
 
 
ChiCTR2000031734: Evaluation Danoprevir sodium tablets combined with ritonavir in the treatment of novel Coronavirus Pneumonia (COVID-19): a randomized, open-label, controlled trial

Recruiting
N/A
40
 
Danoprevir sodium tablets,/ritonavir oral
Huoshenshan Hospital; Huoshenshan Hospital, Ascletis Pharmaceuticals CO., LTD.
Novel Coronavirus Pneumonia (COVID-19)
 
 
ChiCTR2000030472: An open and controlled clinical study to evaluate the efficacy and safety of Ganovo combined with ritonavir in the treatment of novel coronavirus pneumonia (COVID-19)

Recruiting
N/A
20
 
Ganovo/ ritonavir oral+conventional treatment ;Conventional treatment
Shenyang Sixth People's Hospita; Shenyang Sixth People's Hospital, Government
Novel Coronavirus Pneumonia (COVID-19)
 
 
C-DIAMOND, NCT04952207: Effectiveness and Safety of Direct-Acting Antiviral Agents for the Treatment of Chronic Hepatitis C

Recruiting
N/A
300
RoW
Direct-acting antiviral agents, daclatasvir, asunaprevir, ombitasvir, paritaprevir, dasabuvir, sofosbuvir, velpatasvir, ledipasvir, elbasvir, grazoprevir, danoprevir, glecaprevir, pibrentasvir, voxilaprevir
Qing XIe, Gilead Sciences, Tigermed Consulting Co., Ltd
Hepatitis C, Chronic
07/21
08/21
Asclevir (ravidasvir) / Presidio Pharma, Ascletis, Pharco Pharmaceuticals
STORM-C-1, NCT02961426: Strategic Transformation of the Market of HCV Treatments

Active, not recruiting
2/3
603
RoW
sofosbuvir + ravidasvir, ravisdasvir: PPI-668
Drugs for Neglected Diseases, Ministry of Health, Malaysia, Ministry of Health, Thailand, National Science and Technology Development Agency, Thailand
Hepatitis C
08/21
03/24
NCT04885855: 8- Versus 12-week of Sofosbuvir-ravidasvir Treatment of Chronic Hepatitis C

Completed
2/3
322
RoW
Sofosbuvir 400 MG, Grateziano, Ravidasvir 200mg, PPI-668
Muhammad Radzi Abu Hassan
Hepatitis C
12/23
03/24
ChiCTR2000041303: Study on the effect of food on ASC16 tablets pharmacokinetics

Completed
1
16
 
ASC16 tablet
Hu'nan Provincial Maternal and Child Health Care Hospital; Ascletis BioScience Co., Ltd., Self-finance
Basic Science
 
 
ASC-09 / J&J
ChiCTR2000029759: Retracted due to lack of patient A multicenter, randomized, open label, controlled trial for the efficacy and safety of ASC09/ Ritonavir compound tablets and Lopinavir/ Ritonavir (Kaletra) and Arbidol tablets in the treatm

Suspended
N/A
60
 
Lopinavir / Ritonavir (Kaletra) and IFN aerosol inhalation ;Abidol and IFN aerosol inhalation. ;ASC09/ Ritonavir (ASC09F) and IFN aerosol inhalation
The Second Affiliated Hospital of Chongqing Medical University; Chongqing Three Gorges Central Hospital, self-financing
Novel Coronavirus Pneumonia (COVID-19)
 
 
ChiCTR2000029603: A Randomized, Open-Label, Multi-Centre Clinical Trial Evaluating and Comparing the Safety and Efficiency of ASC09/Ritonavir and Lopinavir/Ritonavir for Confirmed Cases of Novel Coronavirus Pneumonia (COVID-19)

Recruiting
N/A
160
 
Conventional standardized treatment and ASC09/Ritonavir ;Conventional standardized treatment and Lopinavir/Ritonavir
The First Affiliated Hospital of Zhejiang University School of Medicine; The First Affiliated Hospital, Zhejiang University School of Medicine, Self-financing
novel coronavirus pneumonia (COVID-19)
 
 
denifanstat (TVB-2640) / Sagimet Biosci
NCT05118776: Study to Evaluate the Safety and Efficacy of ASC40 Tablets in Combination With Bevacizumab in Subjects With rGBM

Active, not recruiting
3
136
RoW
ASC40 tablets, TVB-2640, Placebo tablets, Bevacizumab
Ascletis Pharmaceuticals Co., Ltd.
Recurrent Glioblastoma
06/25
06/25
NCT06192264: A Study to Evaluate the Safety and Efficacy of ASC40 (Denifanstat) Tablets in the Treatment of Patients With Moderate to Severe Acne Vulgaris

Completed
3
480
RoW
ASC40
Ascletis Pharmaceuticals Co., Ltd.
Acne
05/25
05/25
NCT06248008: A Study to Evaluate Safety of ASC40 Tablets in Patients with Moderate to Severe Acne Vulgaris

Active, not recruiting
3
240
RoW
ASC40
Ascletis Pharmaceuticals Co., Ltd.
Acne
10/25
03/26
FASCINATE-3, NCT06594523: A Phase 3 Study Evaluating the Safety and Efficacy of Denifanstat in Patients With MASH and F2/F3 Fibrosis

Withdrawn
3
1260
NA
Denifanstat, TVB-2640, Placebo
Sagimet Biosciences Inc.
MASH, NASH, Metabolic Dysfunction-associated Steatohepatitis, Noncirrhotic Metabolic Dysfunction-associated Steatohepatitis, Nonalcoholic Steatohepatitis, Nonalcoholic Fatty Liver
12/30
12/30
FASCINIT, NCT06692283: A Phase 3 Study Evaluating the Safety and Efficacy of Denifanstat in Patients With MASLD and MASH

Withdrawn
3
2000
NA
denifanstat, TVB-2640, Placebo
Sagimet Biosciences Inc.
MASLD, MASH, NASH, Metabolic Dysfunction-Associated Steatotic Liver Disease, Metabolic Dysfunction-Associated Steatohepatitis, Nonalcoholic Steatohepatitis, Nonalcoholic Fatty Liver
06/26
06/27
NCT03032484: TVB- 2640 in Combination With Bevacizumab in Patients With First Relapse of High Grade Astrocytoma

Completed
2
25
US
Bevacizumab, Avastin, TVB-2640
The University of Texas Health Science Center at San Antonio
Astrocytoma
04/20
04/21
NCT05104125: Study to Evaluate the Safety and Efficacy of ASC40 in Subjects With Moderate to Severe Acne Vulgaris

Completed
2
180
RoW
ASC40 25mg, ASC40 50mg, ASC40 75mg, Placebo
Ascletis Pharmaceuticals Co., Ltd.
Acne Vulgaris
04/23
04/23
FASCINATE-2, NCT04906421: Study of TVB-2640 in Subjects With Nonalcoholic Steatohepatitis (NASH)

Hourglass May 2025 - May 2025 : Data for MASH
Completed
2
168
Europe, Canada, US
TVB-2640, Placebo
Sagimet Biosciences Inc.
Metabolic Dysfunction-assocated Steatohepatitis/ Nonalcoholic Fatty Liver Disease
10/23
10/23
NCT03808558: Phase 2 Study of TVB-2640 in KRAS Non-Small Cell Lung Carcinomas

Active, not recruiting
2
18
US
TVB-2640
David E Gerber, Sagimet Biosciences Inc., Cancer Prevention Research Institute of Texas, Gateway for Cancer Research
KRAS Gene Mutation
04/25
12/26
NCT03179904: TVB-2640 and Trastuzumab With Paclitaxel or Endocrine Therapy for Treatment of HER2 Positive Metastatic Breast Cancer

Active, not recruiting
2
19
US
Anastrozole, Anastrazole, Arimidex, ICI D1033, ICI-D1033, ZD-1033, Denifanstat, ASC 40, ASC-40, ASC40, FASN Inhibitor TVB-2640, TVB 2640, TVB-2640, TVB2640, Exemestane, Aromasin, FCE-24304, Fulvestrant, Faslodex, Faslodex(ICI 182,780), ICI 182,780, ICI 182780, ZD9238, Echocardiography, EC, Letrozole, CGS 20267, Femara, Paclitaxel, Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, Trastuzumab, 180288-69-1, ABP 980, ALT02, Biceltis, CANMab, CT-P06, CT-P6, Herceptin, Herceptin Biosimilar PF-05280014, Herceptin Trastuzumab Biosimilar PF-05280014, Herclon, Hertraz, Herzuma, Immunoglobulin G 1 (Human-Mouse Monoclonal RhuMab HER2gamma1-Chain Antihuman p185(Sup c-erbB2) Receptor), Disulfide with Human-Mouse Monoclonal RhuMab HER2 Light Chain, Dimer, Kanjinti, Ogivri, Ontruzant, PF-05280014, QL 1701, QL-1701, QL1701, rhuMAb HER2, RO0452317, SB3, Trastuzumab Biosimilar ABP 980, Trastuzumab Biosimilar ALT02, Trastuzumab Biosimilar CT-P6, trastuzumab biosimilar EG12014, Trastuzumab Biosimilar HLX02, Trastuzumab Biosimilar PF-05280014, Trastuzumab Biosimilar QL1701, Trastuzumab Biosimilar SB3, Trastuzumab Biosimilar SIBP-01, Trastuzumab-anns, Trastuzumab-dkst, Trastuzumab-dttb, Trastuzumab-pkrb, Trastuzumab-qyyp, Trazimera, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, computerized axial tomography, Computerized axial tomography (procedure), Computerized Tomography, CT, CT SCAN, tomography, Magnetic Resonance Imaging, MRI, Magnetic Resonance, Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI Scan, MRIs, NMRI, nuclear magnetic resonance imaging, sMRI, Structural MRI, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Biopsy, BIOPSY_TYPE, Bx
Mayo Clinic, National Cancer Institute (NCI)
Advanced Breast Carcinoma, HER2-Positive Breast Carcinoma, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, HER2-positive Breast Cancer
07/24
12/25
NCT05835180: A Phase I Pharmacokinetic Study of TVB-2640 (Denifanstat) in Subjects With Mild, Moderate, or Severe Hepatic Impairment Compared to Subjects With Normal Hepatic Function

Completed
1
48
Europe, US
TVB-2640 - 50 mg
Sagimet Biosciences Inc.
Non-alcoholic Steatohepatitis, Hepatic Impairment, Cirrhosis
12/23
12/23
MCC-16-MULTI-22, NCT02980029: TVB 2640 for Resectable Colon Cancer Other Resectable Cancers; a Window Trial.

Terminated
1
23
US
TVB-2640, Placebo
Mark Evers, National Cancer Institute (NCI)
Colon Cancer
10/23
10/23
NCT05743621: Study of TVB-2640 in Men With Metastatic Castration-Resistant Prostate Cancer

Recruiting
1
30
US
TVB-2640, Enzalutamide, Xtandi
Weill Medical College of Cornell University, Sagimet Biosciences Inc.
Prostatic Neoplasms, Castration-Resistant
11/25
11/26
TVB-3567 / Sagimet Biosci, Ascletis
NCT06989840: Phase 1 Study to Evaluate the Safety, Tolerability, PK, and PD of TVB-3567 in Healthy Participants With or Without Acne

Recruiting
1
128
US
TVB-3567, Placebo
Sagimet Biosciences Inc.
Acne
12/25
01/26
Enweida (envafolimab) / 3DMed, Ascletis
ChiCTR2200060332: Concurrent chemoradiotherapy with or without recombinant human endostatin (Endo) consolidation with envafolimab in patients with stage III unresectable non-small cell lung cancer (NSCLC)

Not yet recruiting
4
72
 
The dose of Endostar is 7.5 mg/m2, continuous intravenous infusion 5 days a week, starting 5 days before radiotherapy, one cycle every 2 weeks, a total of 4 cycles. Synchronous EP program for 3 cycles. Consolidation therapy with enverolimab was started 14 days to 30 days after the end of radiotherap ;3 cycles of radiotherapy synchronous EP program. 14 days to 30 days after the end of radiotherapy, Envolimumab consolidation therapy was started, 400 mg each time, 28 days/time, until disease progression or intolerance, and the longest treatment time was 1 year.
Jiamusi Cancer Hospital; Jiamusi Cancer Hospital, China International Medical Foundation
Stage III unresectable non-small cell lung cancer
 
 
 

Download Options